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Chapter 1
Introduction
1.1 Natural Products
The use of natural products for medicinal purposes has a long history. For many thousands
of years people have used plant and animal extracts to treat ailments and disease,1 for
example the Sumerians documented the use of medicinal plants over 5000 years ago.2 The
medicinal properties of these traditional natural remedies are often due to the biologically
active secondary metabolites produced by the organism. Morphine (1), an analgesic
and anaesthetic extracted from the opium poppy, Papaver somniferum, was the first
ever natural product commercialised for medicinal use in 1826.1 Natural products, their
derivates and synthetic mimics, have proven to be successful drugs, whereas only 30%
of the new pharmaceuticals introduced between 1981 and 2006 are classified as totally
synthetic.3
O
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H
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Natural product research has seen cyclical favour from the pharmaceutical industry.
Fierce competition from other investigative methods such as combinatorial chemistry
has at times led to diminished interest in natural products.4 The early 1990s saw the
focus shift towards combinatorial chemistry as the next big source of de novo drug
candidates. Unfortunately, combinatorial libraries did not live up to this initial hope and
no combinatorial derived compounds were approved for use as drugs between 1981 and
2002.5 The anticancer agent Sorafenib (marketed as Nexavar by Bayer AG), sanctioned
by the U.S. Food and Drug Administration (FDA) in late 2005, was the first and thus far
only combinatorial chemistry derived drug to be approved for clinical use.3
1
The lack of success in the combinatorial field led to a resurgence in natural products
research toward the end of the last millennium. The ascendancy of natural products can
at least in part be put down to the structural diversity found amongst them, which far
exceeds that found in today’s combinatorial or synthetic libraries.6 An amalgamation of
natural products research with combinatorial chemistry may, in future prove, to be the
way forward, with lead compounds found from natural sources optimised for use as drugs
by combinatorial methods.
1.2 Marine Natural Products
Terrestrial flora and micro-organisms are the traditional source of natural products due
to ease of access. The marine environment however, largely unexplored before the
development of SCUBA in the 1940s,7 is thought to contain over 80% of the world’s
plant and animal species, making it an ideal source of new pharmaceutical leads.8 By
2004 more than 13,000 marine natural products had been reported in the literature.9 One
of the earliest reports which ignited interest in marine natural products was the discovery
of the bioactive arabinosyl nucleosides, spongothymidine (2) and spongouridine (3), from
the sponge Crypotethia crypta, by Bergmann et al. in the early 1950s.10–12 Currently,
three derivates of the arabinoysl nucleosides are used clinically: vidarabine (Ara-A, 4),
azidothymidine (AZT, 5) and cytarabine (Ara-C, 6). Ara-A and AZT are antiviral agents,
while Ara-C is a chemotherapeutic agent.13
ω-Conotoxin (7), isolated by Olivera et al. in 1985 from the marine snail Conus magus
is a bioactive conopeptide.14 Ziconotide (marketed as Prialt by Elan Corporation), the
synthetic equivalent of 7, is used as an intrathecal analgesic for management of severe
chronic pain.15 Ziconotide is the only true marine natural product currently approved for
drug use.16 However, numerous promising drug candidates, including the anticancer agent
dolastatin 10 (8),17 are currently in advanced preclinical and clinical trials.7
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1.3 Marine Sponges
Sponges (phylum Porifera) are primitive aquatic invertebrate organisms, and whilst mul-
ticellular, lack cellular organisation such as tissues or organ systems. They are considered
to be the oldest and most primitive phylum of the animal kingdom (Metazoa).18 Sponges
are characteristically porous as their simple body organisation consists of numerous
channels and chambers.19 To date around 8000 species of sponge have been described,
with perhaps twice that number yet to be characterised.20 Marine sponges account for the
majority of the described species with only about 150 freshwater species known.19
Porifera have long been separated into three classes: Hexactinellida, Demospongiae
and Calcarea (see Table 1.1). Within a particular sponge species characteristics such
as growth, shape and colour can be greatly affected by location and environmental
factors. Because of the plasticity in sponge morphology, sponge classification was
traditionally based on the microscopic skeletal components and skeletal architecture.19
The microscopic skeletal components of sponges consist of mineral spicules (needle-
like structures composed of silica or calcium carbonate) and spongian (collagen) fibres.
Hexactinellida have siliceous spicules, Calcarea have calcium carbonate spicules and
3
Demospongiae have siliceous spicules and/or collagen fibres. The bulk of living sponge
species belong to the latter class.19 Recently, chemotaxanomic trends and molecular
biology have also been used as tools in sponge taxonomic classification leading to the
re-examination of sponge taxonomy. Whilst such new techniques have confirmed the
previous classification to the class level, there has been some reassignment at the order
level and below.21
Table 1.1. Taxonomic classification to order level of phylum Porifera.19
Phylum Class Sub-class Order
Porifera
Calcarea
Calcaronea
Baerida
Leucosolenida
Lithonida
Calcinea
Clathrinida
Murrayonida
Demospongiae
Ceractinomorpha
Agelasida
Dendroceratida
Dictyoceratida
Halichondrida
Halisarcida
Haplosclerida
Poecilosclerida
Verongida
Verticillitida
Homoscleromorpha
Homosclerophida
Tetractinomorpha
“Lithistids”
Astrophorida
Chondrasida
Hadromerida
Spirophorida
Hexactinellida
Amphidiscophora
Amphidiscosida
Hexasterophora
Aulocalycoida
Hexactinosida
Lychnicosida
Lyssacinosida
4
The marine environment’s success as a bountiful source of new compounds may in
part be due to the sessile nature of many marine algae and invertebrates, including
sponges. In order to prevent predation and encroachment many marine organisms have
evolved advanced chemical defence mechanisms. Some of these secondary metabolites
have promising pharmaceutical activity. Unlike the terrestrial environment where flora
surpasses fauna as a source of secondary metabolites, in the marine environment
invertebrate animals are a greater source of secondary metabolites than algae.22 Research
has shown that sponges are a rich source of diverse and often biologically active secondary
metabolites such as terpenoids and steroidal compounds.23–29 These compounds may be
produced by sponges in response to the threat of overgrowth, predation and infection.21
Interestingly, a multitude of compounds isolated from sponges are similar to those isolated
from marine microbial organisms. As some sponges form symbiotic relationships with
micro-organisms, some of the metabolites isolated from sponges may in fact be of
microbial origin.30,31
Many marine sponge-derived natural products have been found to have useful biological
activity. Several compounds with promising anticancer properties are currently in clinical
trials, including discodermolide (9), KRN-7000 (α-GalCer, α-galactosylceramide) (10),
E-7389 (NSC-707389) (11) and HTI-286 (SPA-110) (12).32 Peloruside A (13), a tublin-
stablising agent, with similar activity to the multi-billion dollar chemotherapeutic agent
paclitaxel is also about enter clinical trials.33 Peloruside A was first isolated from the
New Zealand marine sponge Mycale hentscheli by West et al. at Victoria University of
Wellington (VUW) in 1999.34
New Zealand has a large and diverse marine environment. The New Zealand Exclusive
Economic Zone (EEZ), depicted in Figure 1.1, is around 4.2 million km2 (approximately
15 times the land area) and spans over 30◦ of latitude. The EEZ encompasses both
subantarctic and subtropical waters and has an estimated 23,000 species inhabiting it.35
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Figure 1.1. New Zealand EEZ (denoted with a solid white line). Image courtesy of
National Institute of Water and Atmospheric Research (NIWA).
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1.4 Discovery of New Natural Products at VUW
The Marine Natural Products group at VUW utilises several novel techniques in their
efforts to isolate new compounds from marine sources. These include a chromatographic
method, cyclic loading, as well as an NMR based screening process, which are discussed
below.
1.4.1 Cyclic Loading
Crude sponge extracts are typically difficult to concentrate under reduced pressure as
they are often saturated in both polar and non-polar components. Crude extracts contain
a wide range of compounds, from polar compounds such as sugars and amino acids,
through amphiphilic compounds of intermediate polarity to very non-polar compounds
like steroids and triglycerides. Finding a solvent that can accommodate this wide range
of compounds is nearly impossible, which causes further problems for chromatographic
separation. Cyclic loading is a technique developed by the Marine Natural Products group
at VUW to deal with this problem (for a pictorial represenatation of the cyclic loading
process see Scheme 1.1).36 This method involves loading the extract onto poly(styrene
divinylbenzene) (PSDVB) resin. The extract is first passed through the resin, the eluent is
then diluted with H2O and passed back through the column, the dilution and re-passage
is continued until all the compounds of interest have been loaded onto the resin (usually
three dilutions are all that is required). On the first pass through the resin only the most
hydrophobic compounds adsorb to the resin. Then as the eluents are successively diluted
the mobile phase becomes increasingly polar, encouraging the loading of the amiphiphilic
and finally the polar components of the extract onto the stationary phase.
Biologically active metabolites tend to be amphiphilic as they need both hydrophobic
and hydrophilic properties to enable them to be transported to their site of action. The
hydrophilic nature allows solubility in body fluids, whilst the hydrophobic nature allows
permeability through membranes.37 These compounds of intermediate polarity can be
targeted using the cyclic loading method. Once the column is completely loaded, the resin
7
Scheme 1.1. Cyclic loading.
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is sequentially eluted with fractions of increasing amounts of organic modifier (usually
Me2CO or MeOH). The early fractions contain the polar sugars and amino acids whilst
the final fractions contain the lipids and steroids. Compounds at the extremes of the
polarity range tend to be primary metabolites and make up the majority of the extract
mass. The middle fractions contain the compounds of intermediate polarity (amphiphilic
molecules), which tend to be secondary metabolites. Thus cyclic loading allows the
targeting of secondary metabolites (compounds likely to be biologically active), within
one chromatographic step.
Mixtures of Me2CO/H2O are notoriously difficult to concentrate as they are prone to
excessive bumping. Back loading — an adaptation of cyclic loading — is a way of
avoiding this problem. Back loading allows the conversion of the often water-rich cyclic
loading eluents to 100% Me2CO fractions which are easier to concentrate. Cyclic loading
eluents are passed through a PSDVB back loading column, the eluent is diluted two-
fold and passed back through the column, the eluent is again diluted two-fold and passed
through the column, ensuring all compounds have been adsorbed onto the resin. The resin
is then washed with water before being eluted with 100% organic modifier. The eluent,
now water free, is then concentrated under reduced pressure.
1.4.2 NMR Based Screening
The major advantage of traditional bioassay-guided natural product isolation is the
guaranteed isolation of compounds with the desired bioactivity, however this method
has several flaws. Firstly, a minor compound may be overlooked if the biological
activity of a more major compound in the mixture overwhelms the activity of the minor.
Secondly, the dereplication of known compounds is a major problem of bioassay-guided
isolation. In recent times, several natural products groups have started to utilise NMR
guided isolation in an attempt to avoid these problems. The majority employ LC-NMR
for dereplication,38 whilst a few groups, including the Marine Natural Products group
at VUW, use more unusual NMR based methods.36,39–41 The Gerwick and Kobayashi
groups report using diffusion edited NMR to help with dereplication.42,43 Schroeder and
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co-workers report using differential analysis of 2D NMR spectra to characterise crude
unfractionated extracts.44 The Marine Natural Products group at VUW has developed a
2D NMR-based screening method to assess crude sponge extracts (Appendix A).36,39–41
The screening technique allows researchers to target sponges which are rich producers of
potentially novel secondary metabolites.
Sponge samples are extracted in MeOH and cyclic loaded on to PSDVB resin. The resin
is eluted with H2O, 30% Me2CO/H2O, 75% Me2CO/H2O and 100% Me2CO. The 75%
Me2CO/H2O fraction is assumed to represent the majority of the amphiphilic molecules
and is therefore analysed using 1D and 2D NMR. The HSQC experiment, one of the 2D
NMR spectra obtained on the 75% Me2CO/H2O fraction, shows direct proton to carbon
connectivity. Thus the HSQC screen has the potential to identify unusual functional
groups.
A computer generated “mask” of additive HSQC data of all previously screened sponge
samples in our laboratory has been created (see Figure 1.2, common correlations appear
white whilst less common correlations appear blue). The HSQC data of new sponge
extracts are compared to this mask. HSQC correlations are classified as either common
(green peaks) or uncommon (red peaks). The threshold at which correlations are classified
as uncommon are those correlations seen in 3% or less of the sponge samples. Two
sponge extract screens have been used as illustrative examples of the extremes. Figure
1.3 is an example of an “uninteresting” extract — with a high number of common HSQC
correlations (green peaks), whilst Figure 1.4 is an example of an “interesting” extract —
with a high number of uncommon HSQC correlations (red peaks). Correlations that are
frequently observed are from compounds that are common amongst the screened sponges
and are therefore likely to be primary metabolites. Thus, uncommon correlations may
indicate the presence of secondary metabolites. The intensity of a particular correlation
indicates the relative amount of the compound present in the sponge. The promise of
each new sponge sample is assessed and ranked based on 1) the number of uncommon
HSQC correlations, 2) the intensity of uncommon HSQC correlations, 3) the functionality
these peaks represent, 4) the amount of sponge collected and 5) the recollectability of the
sponge. These criteria are not weighted equally.
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Figure 1.2. Computer generated “mask” of HSQC data
Figure 1.3. HSQC mask applied to a crude screen of an “uninteresting” extract.
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Figure 1.4. HSQC mask applied to a crude screen of an “interesting” extract.
1.4.3 Sponges Examined in this Research
In this study, five sponges were investigated based on their results in the screening
protocol. These sponge samples had been previously screened and assessed by other
members of the Marine Natural Products group at VUW. Darwinella oxeata, appeared
the most interesting and further investigation into this sponge is discussed in Chapter 3.
Dictyodendrilla dendyi and Raspailia topsenti as well as two unidentified sponge species,
MNP0996 and MNP1003, were briefly investigated and are discussed in Chapter 2.
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Chapter 2
Sponges Examined by Spectroscopic Screening
As well as a thorough investigation of Darwinella oxeata described in Chapter 3, four
other New Zealand marine sponges were briefly investigated in the course of this study,
Dictyodendrilla dendyi and Raspailia topsenti, and two unidentified sponge species,
MNP0996 and MNP1003. These sponges were selected for investigation based on
their promising results in the 2D NMR based screening method (previously discussed
in Chapter 1, Section 1.4.2) and the results of previous work on Dictyodendrilla dendyi
and Raspailia topsenti.40,45
Each of the four sponges were extracted in MeOH and their extracts were cyclic loaded
onto reversed-phase PSDVB resin. The resins were then batch eluted with increasing
amounts of Me2CO in H2O and the fractions analysed by NMR, leading to a short study
of Dictyodendrilla dendyi and Raspailia topsenti. No further investigation of MNP0996
or MNP1003 occurred, as the majority of this study focused on the bountiful Darwinella
oxeata sample discussed in Chapter 3. Notable features of the four sponge extracts are
discussed in the following sections.
2.1 Investigation of Dictyodendrilla dendyi
Due to its deep blue to black colouring, Dictyodendrilla dendyi (see Figure 2.1) is a
very distinctive keratose sponge.19 This species had been previously worked on in our
laboratory by Ryan, who reported the isolation of seven new lamellarins and one new
dictyodendrin.40 Notably, many of these new compounds were isolated from relatively
polar cyclic loading fractions (20% Me2CO/H2O and 40% Me2CO/H2O).
40 The success
of Ryan, along with its promising result in the HSQC screen depicted in Figure 2.2, led
to the brief re-investigation of this species in this study. The HSQC screen showed many
interesting and uncommon signals in the aromatic region (Figure 2.2).
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Figure 2.1. Underwater photo of Dictyodendrilla dendyi, courtesy of Peter Northcote.
Figure 2.2. HSQC mask applied to the crude screen of Dictyodendrilla dendyi.
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Interestingly, the methanolic extract of Dictyodendrilla dendyi was almost black in colour.
On completion of the cyclic loading process, the diluted eluent, which is normally
discarded at this stage, had retained this colour. The diluted eluent would have contained
only the most polar compounds that had not previously adsorbed to the PSDVB resin
during the cyclic loading process (see Scheme 1.1). The diluted eluent was then saturated
with NaCl, and loaded onto another column of PSDVB. The NaCl appeared to facilitate
the adsorbtion of the black pigment onto the resin as the eluent was lighter and the
resin appeared to discolour (from white to grey). This column was then eluted with
Me2CO. NMR analysis of this fraction along with the other fractions (generated during
cyclic loading) proved interesting. In an attempt to isolate the compound or compounds
responsible for the black colour many different types of chromatography were performed,
including normal phase and size exclusion columns. The source of the black colouration
was not isolated. However, in the process of tracking the black coloured residue the
known compound lamellarin θ 4′′,4′′′-disulfate (14) was isolated. No further investigation
was undertaken as there was no sign of lamellarins or dictyodendrins not previously
isolated by this research group.
NH
OSO3--O3SO
OMe
OO
OH
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2.2 Investigation of Raspailia topsenti
Raspailia topsenti, an orange finger sponge (see Figure 2.3),19 had previously been
extensively worked on in our laboratory by West, Moraes, Ryan and Dowle leading to
the isolation of thirteen new clerodane diterpenes.36,40,45,46 The previous success of this
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species as a source of new compounds along with its promising result in the HSQC screen
as shown in Figure 2.4 led to another brief re-investigation of this species in this study.
Figure 2.3. Underwater photo of Raspailia topsenti, courtesy of Alan Duckworth.
The HSQC screen showed a large amount of uncommon resonances (red peaks in Figure
2.4), which were predominantly in the oxymethine, aliphatic and aromatic regions. NMR
analysis of some of the cyclic loading factions had signals reminiscent of the clerodane
diterpenes with some structural features not seen in known compounds. Repeated
normal phase columns were performed in attempts to isolate further metabolites of R.
topsenti. Unfortunately, due to the paucity of these metabolites, no new compounds were
isolated. Further analysis was discontinued but when new populations of this sponge are
encountered they will warrant reinvestigation.
16
Figure 2.4. HSQC mask applied to the crude screen of Raspailia topsenti.
2.3 Investigation of Two Unidentified Sponge Species
Promising HSQC screen results lead to the brief investigation of two unidentified sponges,
MNP0996 and MNP1003. The HSQC screen of MNP0996 (Figure 2.5) shows a variety
of low intensity uncommon resonances whilst the screen of MNP1003 (Figure 2.6) shows
a variety of uncommon resonances with a slightly higher intensity.
Interestingly the mass of the 20% Me2CO/H2O fraction of MNP0996 was unexpectedly
high when compared to the masses of the other fractions. Attempts to obtain a 1H NMR
spectrum of this fraction were relatively unsuccessful as it was not completely soluble in
CD3OD, d6-DMSO or D2O.
The 1H NMR analysis of the other cyclic loading fractions of MNP0996 and MNP1003
showed some interesting resonances, despite this no further analysis was performed, as
the focus of the study shifted to Darwinella oxeata (Chapter 3). However both sponges
warrant further investigation by another researcher.
17
Figure 2.5. HSQC mask applied to the crude screen of MNP0996.
Figure 2.6. HSQC mask applied to the crude screen of MNP1003.
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Chapter 3
Investigation of Darwinella oxeata
3.1 Darwinella oxeata
A large group within the Demospongiae class, known as keratose sponges (encompass-
ing the Dendroceratida, Dictyoceratida and Verongida orders), lack mineral spicules
and instead possess spongian fibres which reinforce the sponge matrix.19 Taxonomic
classification of keratose sponges relies on such factors as fibre arrangement and
chemotaxonomic trends. The isolation of spongian diterpenes from keratose sponges
in part led to the revision of the Dendroceratida order in 1990.21 Keratose sponges lack
the physical protection of spicules and are thus a target for predation.19 The high levels
of secondary metabolites isolated from the keratose sponges may be an example of the
evolutionary response to the enhanced threat of predation.
Darwinella oxeata belongs to the family Darwinellidae, which, along with Dictyoden-
drillidae, are members of the Dendroceratida order (Table 3.1). D. oxeata (Figure 3.1) is a
sulfur yellow coloured, thin, encrusting sponge most commonly located on steep-sloping
reefs and canyon walls at depths around 15 m.47 It is found throughout New Zealand and
Australian waters.47,48 The species, whilst lacking inorganic spicules, can be distinguished
from other Darwinella species by the notched surface of its spongian fibres.47 Collections
of this species from Australasian waters have in the past been misidentified as Aplysilla
sulphurea due to similar surface pigmentation and morphology.19,48,49 Hooper and van
Soest believe that there is a very low incidence of Aplysilla within Australasia and that
the majority of common encrusting darwinellids are species of Darwinella.19
19
Figure 3.1. Underwater photo of Darwinella oxeata, courtesy of Kel Nairn.
Table 3.1. Taxonomic classification of genus Darwinella from order Dendroceratida.19
Order Family Genus Species
Dendroceratida
Darwinellidae
Aplysilla
Chelonaplysilla
Darwinella oxeata
Dendrilla
Dictyodendrilidae
Acanthodendrilla
Dictyodendrilla
Igernella
Spongionella
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3.2 Chemical Ecology of Darwinella oxeata
Nine compounds have been reported from Darwinella oxeata, including 132,173-cyclo-
pheophorbide (15), the first porphyrin reported from a sponge.41,48–50 The majority of
the compounds isolated from this sponge are in fact rearranged spongian diterpenoids
with the aplysulphurane backbone (16).41,48,49,51 The first compound reported from
D. oxeata was aplysulphurin (17) in 1984.48 Though the sponge was initially identified
as Aplysilla sulphurea, it was later reclassified in 1986 by the same group.49 The
tetrahydroaplysulphurins -1 (18), -2 (19) and -3 (20) were reported by Karuso et al. in
1986.49 Most recently, Wojnar reported four nitrogenous rearranged spongian diterpenes
in 2008: oxeatamide A (21), oxeatamide A 23-methyl ester (22), iso-oxeatamide A (23)
and oxeatamide B (24).41
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3.2.1 Isolation of New Nitrogenous Aplysulphuranes fromDarwinella
oxeata
A sponge identified as Darwinella oxeata was collected from Archway Bay, Cape Brett,
Northland. A sample of this sponge was screened by other researchers in the Marine
Natural Products Group at VUW, using the screening protocol described in Chapter 1.
The screen was assessed as promising due to the high number of uncommon HSQC
correlations that can be seen in red in Figure 3.2.
Figure 3.2. HSQC mask applied to the crude screen of Darwinella oxeata.
The sponge was extracted in MeOH and the extract was cyclic loaded on to a column
of reversed-phase PSDVB resin. The resin was batch eluted with increasing amounts of
Me2CO in H2O and the fractions analysed by NMR. The
1H NMR spectra of the 20%
and 40% Me2CO/H2O fractions appeared to contain one main compound, later identified
as the known compound oxeatamide A (21). Further chromatographic steps employing
bench-top normal-phase chromatography followed by reversed-phase HPLC (depicted
in Scheme 3.1) led to the isolation of three known compounds oxeatamide A (21), iso-
oxeatamide A (23) and oxeatamide B (24), and one new compound, oxeatamide C (25).
The NMR spectra of the 60% Me2CO/H2O fraction showed a mixture of structurally
similar compounds and contained many interesting resonances. Futher chromatographic
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steps including normal-phase bench-top chromatography followed by reversed-phase
HPLC (Scheme 3.2), led to the isolation of four new compounds oxeatamides D (26),
E (27), F (28) and G (29), as well as two known compounds membranolides C (30)52 and
D (31).52
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Darwinella oxeata (535 g)
MeOH (x2)
Solids Extract
0% 20% 40% 60% 80% 100%
0% 1% 2% 5% 10% 20% 50% 0% 1% 2% 5% 10% 20%
HP20, Me2CO/H2O
DIOL, CH2Cl2/MeOH DIOL, CH2Cl2/MeOH
50%
19.5-23.5 min
Oxetamide A
70% MeOH/0.1 M HCOOH(aq.)
70% MeOH/0.1 M HCOOH(aq.)
7.8-15.4 min
Oxeatamide C
20.2-23.8 min
Oxeatamide A
4.5-8.5 min 20.8-23.5 min
Oxeatamide A
24.5-26.5 min
70% MeOH/0.1 M HCOOH(aq.)
80% MeOH/0.1 M HCOOH(aq.)
8.2-9.7 min
Iso-oxeatamide A
10.1-14.8 min
Oxeatamide B
60% MeOH/0.1 M HCOOH(aq.)
C18, HPLC
A B C
Scheme 3.1. Isolation of oxeatamides A (21), B (24) and C (25), and iso-oxeatamide A
(23).
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Darwinella oxeata (535 g)
MeOH (x2)
Solids Extract
0% 20%
A
40%
B
60%
C
80% 100%
0% 1% 2% 5% 10% 20%
50%
DIOL, CH2Cl2/MeOH
HP20, Me2CO/H2O
DIOL, CH2Cl2/MeOH
0% 1%
40-42
50%0% 1%
25-29
50%
DIOL, CH2Cl2/MeOH
0%-1%
13-39
17.2-19.1 min
Oxeatamide D
20.0-22.4 min
Oxeatamide E
22.5-24.3 min
Oxeatamide F
24.3-26.7 min
Oxeatamide G
23.3-25.3 min
Oxeatamide E
25.5-27.1  min
Oxeatamide F
27.1-28.5 min
Oxeatamide G
C18, 70% MeOH/0.1 M HCOOH(aq.), HPLC
16.8-18.9 min
Membranolide C
19.8-23.3 min
Membranolide D
Scheme 3.2. Isolation of oxeatamides D (26), E (27), F (28) and G (29), and
membranolides C (30) and D (31).
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3.3 Known Compounds Isolated from Darwinella oxeata
Five known compounds were isolated from Darwinella oxeata, oxeatamides A (21), B
(24), iso-oxeatamide A (23) and membranolides C (30) and D (31).
3.3.1 Oxeatamide A, B and Iso-oxeatamide A
Purification with HPLC led to the isolation of oxeatamides A (21), B (24) and iso-
oxeatamide A (23). As these compounds had been recently isolated by Wojnar, another
member of the Marine Natural Products group at VUW, they were readily identified by
comparison of their NMR data.41
3.3.2 Membranolide C and D
Use of HPLC led the isolation of two impure compounds with a different chromophore
to the oxeatamides (depicted in diode array trace, Figure 3.3). Preliminary NMR analysis
showed similarites to the aplysulphurane diterpene skeleton (16) of the oxeatamides,
however the signals characteristic of the nitrogenous moiety were notably absent and
instead two acetal signals were apparent. A literature search of the aplysulphurane class
and comparison of the NMR data revealed the compounds to be membranolides C (30)
and D (31). Membranolides C (30) and D (31) had not previously been isolated from
Darwinella oxeata, however Ankisetty et al. reported 30 and 31 from the Antarctic sponge
Dendrilla membranosa in 2004.52
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Figure 3.3. Diode array trace of HPLC separation of the membranolides C (30) and D
(31), and oxeatamides E (27), F(28) and G (29).
3.4 New Oxeatamides Isolated
Five new oxeatamides were isolated from Darwinella oxeata. Oxeatamide C (25) was
isolated from an early polar fraction that was also found to contain three previously
reported oxeatamides — oxeatamide A (21), iso-oxeatamide A (23) and oxeatamide B
(24) — as detailed in Scheme 3.1. Oxeatamides D to G (26–29) were isolated from a
mid-polarity fraction that also contained membranolides C (30) and D (31), as detailed in
Scheme 3.2. The diode array trace of the HPLC separation of oxeatamides D to G (26–29)
is depicted in Figure 3.4. The structure elucidation of these new compounds follows, a
summary of the new structures can be found on page 58.
26 27 28 29
Figure 3.4. Diode array trace of HPLC separation of oxeatamides D, (26) E (27), F(28)
and G (29).
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3.4.1 Oxeatamide D
Due to the relative lack of spectral overlap and the fact that oxeatamide D (26) possessed
only one nitrogen and one set of aromatic ring signals, the structure of 26 was elucidated
first.
The molecular formula C24H35NO3 was determined for oxeatamide D (26) by HRESIMS
with the [M + Na]+ pseudomolecular ion at m/z 408.2520 (∆ 1.2 ppm), requiring eight
double bond equivalents. The 13C NMR spectrum contained only 19 resonances,
however an additional five resonances were observed in the HSQC and/or HMBC
spectra, accounting for all carbons present in the formula. The 1H NMR spectrum
accounted for 34 protons, suggesting one exchangeable proton. Initial analysis of the
13C and multiplicity-edited HSQC spectra revealed 16 protonated carbons, six methyls,
six methylenes and four methines leaving eight non-protonated carbons. Some carbon
resonances were tentatively assigned due to their typical chemical shift values: a
carboxylic acid/ester carbonyl C-6 (δC 175.8), an amide/lactam carbonyl C-16 (δC 168.4)
and aromatic resonances C-8 (δC 134.3), C-9 (δC 150.3), CH-11 (δH 7.61; δC 127.6),
CH-12 (δH 7.68; δC 122.4), C-13 (δC 131.6) and C-14 (δC 141.3).53 The presence of
an aromatic ring was supported by the typical aromatic chemical shifts of the proton
resonances attached to the two aromatic methines.53 The two carbonyl groups and the
aromatic ring system accounted for six double bond equivalents suggesting the compound
contained two other ring systems.
COSY correlations between methylene H2-1 (δH 2.36, 1.47; δC 41.0) and methylene H2-2
(δH 1.82, 1.66; δC 20.0), and between H2-2 and methylene H2-3 (δH 1.33, 1.27; δC 39.6)
established the methylene chain CH2-1 to CH2-3 (Figure 3.5).
COSY
1
2
3
Figure 3.5. COSY correlations establishing connectivity of C-1 to C-3 of
oxeatamide D (26).
Analysis of the HMBC spectrum showed four correlations from H3-20 (δH 1.46; δC 32.9)
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to C-1, C-5 (δH 2.06, 1.51; δC 50.8), C-10 (δC 39.7) and C-9. As a methyl singlet, CH3-20
must be attached to the alkyl quaternary carbon C-10 which in turn must be adjacent to
C-1, C-5 and C-9. The assignment of C-5 and C-10 as adjacent carbons was supported
by HMBC correlations observed from H-5b to C-10 and C-20, in conjunction with long-
range W-coupling observed in the COSY spectrum between H-1a and H-5a (Figure 3.6).
CH3
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Hb
Ha Hb
COSY (Long Range)
HMBC
Figure 3.6. Key HMBC and COSY correlations establishing the connectivity around the
quaternary centre C-10 of oxeatamide D (26).
A gem-dimethyl moiety was established from HMBC correlations from H3-18 (δH 0.41;
δC 27.3) and H3-19 (δH 0.91; δC 32.9) to each other’s carbons, their attachment point C-4
(δC 31.8) and to the methylene carbons C-3 and C-5 on either side. An HMBC correlation
from H2-5 to C-4 was also evident. HMBC correlations from H3-18 and H3-19 to C-3
indicated that the gem-dimethyl moiety was attached to the CH2-3 side of the methylene
chain fragment. This established substructure A (depicted in Figure 3.7), as a trimethyl
substituted cyclohexane ring.
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CH3H3C
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Figure 3.7. Key HMBC correlations establishing the connectivity of the cyclohexane
ring, substructure A, of oxeatamide D (26).
Six aromatic signals were observed in the 13C NMR consisting of two methines, CH-
11 and CH-12, and four non-protonated carbons C-8, C-9, C-13 and C-14, suggesting a
tetra-substituted benzene ring. The aromatic methine protons H-11 and H-12 appeared
as doublets in the 1H NMR spectrum with a coupling constant of 8.1 Hz, indicating
ortho placement,53 this was supported by the COSY correlation observed between them.
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HMBC correlations observed from the protons of the two aromatic methines helped to
define the connectivity of the ring. The HMBC experiment is generally optimised for XJCH
of 8 Hz. HMBC correlations in aromatic systems are unusual as 3JCH values are typically
larger than 2JCH values; in benzene the 2JCH is 1.0 Hz whilst the 3JCH is 7.4 Hz.53 Thus
two-bond HMBC correlations usually appear weaker than three-bond HMBC correlations
in aromatic systems. Proton H-11 showed strong HMBC correlations to C-13 and C-8,
indicating three-bond connectivity and weak HMBC correlations to C-9 indicating two-
bond connectivity. Strong HMBC correlations observed from H-12 to C-9 and C-14
indicated three-bond connectivity, while weak HMBC correlations were also observed to
C-11 and C-13 indicating two-bond connectivity, allowing the assignment of the aromatic
positions and establishing substructure B, depicted in Figure 3.8.
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Figure 3.8. COSY and HMBC correlations establishing substructure B of
oxeatamide D (26).
COSY correlations observed between methine H-7 (δH 4.75; δC 40.5) and methyl H3-17
(δH 1.63; δC 15.5) suggested that C-7 and C-17 were adjacent carbons. This was supported
by the doublet signal observed in the 1H NMR for H3-17, which indicated methyl CH3-17
was attached to a methine. Correlations apparent in the HMBC spectrum from H-7 and
H3-17 to the carbonyl resonance C-6 (δC 175.8) suggested that C-6 was adjacent to CH-7
establishing substructure C (Figure 3.9).
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Figure 3.9. COSY and HMBC correlations used to establish substructure C of
oxeatamide D (26).
The substitution pattern of the aromatic ring (depicted in Figure 3.10) was assigned based
on HMBC correlations observed to and from positions of the aromatic ring. HMBC
correlations observed from H-11 of the aromatic ring to C-10 of the cyclohexyl ring ,
and similarly from H-5b of the cyclohexyl ring to C-9 of the aromatic ring as well as
from CH3-20 to C-9 placed the cyclohexane ring (substructure A) attached to C-9 and
ortho to H-11. HMBC correlations from H-7 and H3-17 to C-8 were used to position
substructure C as the substituent at C-8.
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Figure 3.10. Placement of aromatic substituents of oxeatamide D (26).
A second carbonyl C-16 (δC 168.4) was positioned adjacent to C-13 based on HMBC
correlations observed from H-12 to C-16. HMBC correlations from H2-15 to C-14 and
C-8 suggested CH2-15 (δH 4.38, 4.21; δC 50.1) was adjacent to C-14. HMBC correlations
were observed from H2-15 to C-13 and C-16. The chemical shift of C-16 (δC 168.4) was
consistent with that of the carbonyl of a lactam (150 ppm–185 ppm) and CH2-15 has
1JCH
of 140 Hz consistent with that for a carbon adjacent to nitrogen.53 The chemical nature of
CH2-15 and C-16 along with the HMBC correlations observed from H2-15 suggested the
presence of a lactam ring (depicted in Figure 3.11) which also accounted for the remaining
double bond equivalent.
31
HMBC
H
H
21
12
13
14
15
16
N
O
HH
O
Figure 3.11. HMBC correlations used to establish the connectivity of the lactam ring in
oxeatamide D (26).
The NMR data for the aromatic ring and lactam of oxeatamide D (26) were compared
to that for oxeatamide A (21) and iso-oxeatamide A (23) to ensure the correct structural
isomer of the lactam was assigned (Table 3.2). In 21 the lactam carbonyl is adjacent to
C-13 whilst in 23 the lactam carbonyl is adjacent to C-14. The placements of the lactam
carbonyl affects the 1H NMR resonance of the aromatic methine proton H-12. In 21, the
aromatic methine proton H-12 appears at 7.63 ppm compared to 7.23 ppm for 23. Thus,
the placement of the lactam carbonyl adjacent to C-14, as opposed to C-13, caused the
upfield shift of the H-12 resonance in the 1H NMR spectrum. The chemical shift of H-
11 was not greatly affected by the position of the lactam carbonyl, 7.58 ppm for 21 and
7.61 ppm for 23. The lactam carbonyl placement also affects the chemical shifts of C-13
and C-14 . The 1H and 13C NMR data for 26 were consistent with that for 21, supporting
the placement of the lactam carbonyl adjacent to C-13.
Table 3.2. Comparison of the 13C and 1H NMR chemical shifts (CDCl3) for
oxeatamide A (21), iso-oxeatamide A (23) and oxeatamide D (26).
N
8
9
11
12
13
14
15
16
O
21
δC (ppm) δH (ppm)
Position 21* 23* 26 21* 23* 26
8 135.2 139.4 134.3
9 151.5 146.8 150.3
11 127.8 130.4 127.6 7.58 7.61 7.61
12 122.7 121.4 122.4 7.63 7.23 7.68
N
8
9
11
12
13
14
15
16
O
23
13 130.2 140.9 131.6
14 142.0 130.4 141.3
15a 50.2 170.0 50.1 4.40 – 4.3815b 4.31 – 4.21
16a 169.4 49.8 168.4 – 4.37 –16b – 4.28 –
*Wojnar, J. M. Isolation of Novel Secondary Metabolites from New Zealand Marine Organisms, Ph.D. thesis,
Victoria University of Wellington, 2008.
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With the carbon skeleton of the oxeatamide backbone (32) established, 20 of the 24
carbons and 25 of the protons were accounted for, leaving a fragment as well as an
oxygen and exchangeable proton unassigned. The chemical shift of the C-6 carbonyl
was typical of a carboxylic acid,53 and thus the exchangable proton and oxygen were
assumed to be attached to C-6. Also supporting this assumption was the fact that all the
double bond equivalents were already accounted for, precluding a lactone as found in
other spongian diterpenes.21 The carboxylic acid functionality at C-6 was consistent with
the chromatographic behaviour observed (use of HCOOH(aq.) during HPLC as detailed in
Scheme 3.2) and the known oxeatamides.41
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Methyls CH3-24 (δH 0.92; δC 20.1) and CH3-25 (δH 0.92; δC 20.1) have the same chemical
shifts in both the 1H and 13C NMR spectra, implying identical chemical environments.
COSY and HMBC correlations were observed from H3-24 and H3-25 to the methine CH-
23 (δH 2.02; δC 27.8), and attached CH3-24 and CH3-25 to CH-23, in an isopropyl moiety.
HMBC correlations were apparent from H-23, H3-24 and H3-25 to a methylene C-22
(δH 3.38, 3.35; δC 50.0) indicating that C-23 and C-22 were adjacent carbons. Further
correlations were observed in the HMBC spectrum from H2-22 to C-15 and C-16 of
the lactam ring, these in conjuction with A 1JCH of 137 Hz for CH2-22 —consistent
for a carbon attached to nitrogen— led to the establishment of the N-substituted lactam,
depicted in Figure 3.12. The nitrogenous moiety N-21 to C-25 is proposed to arise from
a reaction between a terpene precursor and the decarboxylated amino acid valine, this is
discussed in more detail in Section 3.6.2.
Whilst the molecular formula of oxeatamide D (26) differs from that of the known
oxeatamides,41 detailed analysis of the 1H, 13C, COSY, HSQC and HMBC showed
similar NMR data and structural parallels to oxeatamides A (21) and B (24) with the
common oxeatamide backbone (32) C20H26NO3 identified. The oxeatamide backbone
(32) accounted for all but C4H9 of the determined molecular formular of 26. The
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Figure 3.12. COSY and key HMBC correlations establishing the attachment and
connectivity of the C-22 to C-25 fragment of oxeatamide D (26).
placement of the 3-methylpropyl (C4H9) fragment, as a substituent of N-21 of the lactam
ring completed the structure elucidation of oxeatamide D (26). Therefore the structure of
oxeatamide D is given as 26 with NMR data presented in Table 3.3.
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3.4.2 Relative Configuration of Oxeatamide D
Interestingly the 2D NOESY spectrum of oxeatamide D (26) obtained in CDCl3 resulted
in negative correlations, some of which appeared to be inter- rather than intramolecular.
This was consistent with the all negative NOE enhancements observed by Wojnar for
oxeatamide A (21) in CDCl3.41 The sign of NOE enhancements are dependent on several
factors, including the size of the molecule, the strength of the magnetic field, and the
temperature at which the spectrum is run at. It is possible that in CDCl3 (a non-hydrogen
bonding solvent), 26 is able to exist as 1H-bonded dimers. By running the NOESY
spectrum of 26 in a protic solvent, CD3OD, dimerisation can not occur and thus positive
NOE enhancements were observed.
Oxeatamide D (26) has two chiral centres C-7 and C-10 at which relative configuration
was established using selected key NOE enhancements and long-range COSY correla-
tions, depicted in Figure 3.13. NOE enhancements observed between methine CH-11
of the benzene ring and H-2a and H3-18 as well as 1,3-diaxial enhancements observed
between H-2a and H3-18 implied that the benzene ring was on the same face of the
cyclohexane ring as CH3-18 and H-2a, and that they were all axial. The placement of
C-9 as axial on the top face implies that methyl C-20 was equatorial.
Also consistent with the major conformer were the W-couplings observed between CH3-
18 and H-5b and between H-5a and H-1a, placing H-5b axial on the bottom face and H-5a
equatorial on the top side. Thus, the major conformer of the ring has H-1a equatorial, H-
2a axial, CH3-18 axial, H-5b equatorial and C-9 axial on the top face and H-1b axial,
H-2b equatorial, CH3-19 equatorial, H-5b axial and C-20 equatorial on the bottom face.
The configuration of methylene protons H-3a and H-3b was not assigned as there was
spectral overlap of their 1H NMR resonances. The relative configuration of chiral centre
C-10 was thus assigned to be S*.
NOE enhancements were observed between H3-17 and H-5a and H3-18. An NOE
enhancement was also seen between H3-17 and H-15a. These NOE enhancements, in
conjunction with NOE enhancement observed between H-7 and CH3-20, were used to
establish the relative configuration of chiral centre C-7 as R*.
36
Typically for molecules with cyclohexane rings the molecule adopts a conformation
where bulky substituents such as phenyl rings are placed equatorially.54 For the mem-
branolides and known oxeatamides, which all possess cyclohexane rings, the benzene
substituent of the cyclohexane ring is in fact axial.41,52,55 This unusual axial placement of
the benzene substituent of a cyclohexane ring was also seen in oxeatamide D (26). The
overall relative configuration assigned to 26, 7R* 10S*, was consistent with the known
compounds.41,52,55
37
Figure 3.13. Key NOE enhancements of oxeatamide D (26) establishing the relative
configuration. W-coupling shown in red.
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3.4.3 Oxeatamide E
The HRESIMS pseudomolecular ion observed at m/z 456.2518 ([M + Na]+) was used
to determine the molecular formula C28H35NO3, ∆ 0.7 ppm, for oxeatamide E (27),
which required 12 double bond equivalents. The 13C NMR spectrum contained 26
unique resonances leaving two carbon resonances unaccounted for, indicating spectral
overlap or symmetry. The 1H NMR spectrum accounted for only 34 protons, again
suggesting the likely presence of one exchangeable proton. Initial analysis of the 13C
and multiplicity-edited HSQC NMR spectra revealed 17 unique protonated carbons, four
methyls, seven methylenes and six methines, leaving nine non-protonated carbons. The
ten aromatic resonances observed indicated the presence of two aromatic aromatic rings.
This along with the tentative assignment of a carboxylic acid/ester carbonyl (δC 176.8)
and an amide/lactam carbonyl (δC 168.4),53 accounted for ten double bond equivalents,
suggesting the compound contained two other ring systems.
In a similar manner to oxeatamide D (26), the methylene chain CH2-1 to CH2-3 was
established via COSY correlations between H2-1 (δH 2.34, 1.47; δC 40.9) and H2-2
(δH 1.81, 1.66; δC 20.0) and between H2-2 and H2-3 (δH 1.31, 1.29; δC 39.6). Four
correlations were observed in the HMBC spectrum of oxeatamide E (27) from methyl H3-
20 (δH 1.44; δC 32.8) to C-1, C-5 (δH 2.03, 1.50; δC 50.7), C-10 (δC 39.7), C-9 (δC 150.5).
Like oxeatamide D (26), CH3-20 must therefore be attached to the alkyl quaternary carbon
C-10 which in turn is adjacent to C-1, C-5 and C-9. Long range W-coupling observed in
the COSY spectrum between H-1a and H-5a in conjunction with the HMBC correlations
observed from H2-5 to C-1, C-10 and C-20, indicated C-5 and C-10 were adjacent. HMBC
correlations from methyls H3-18 (δH 0.38; δC 27.1) and H3-19 (δH 0.91; δC 33.0) to each
other, their attachment point C-4 (δC 31.8) and to the methylene carbons C-3 and C-5
on either side, were used to establish the gem-dimethyl moiety and placed it between C-3
and C-5. An HMBC correlation from H2-5 to C-4 was also evident. Thus the cyclohexane
ring of oxeatamide E (27), depicted in Figure 3.14, was established.
In oxeatamide E (27) 10 unique aromatic signals were observed in the 13C NMR
consisting of five distinct methine resonances, CH-11 (δH 7.59; δC 127.5), CH-12
40
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Figure 3.14. COSY and key HMBC correlations establishing connectivity of
cyclohexane ring of oxeatamide E (27).
(δH 7.67; δC122.0), CH-25[29] (δH 7.20; δC 128.8), CH-26[28] (δH 7.25; δC 128.6) and
CH-27 (δH 7.19; δC 126.5), and five non-protonated carbons C-8 (δC 135.1), C-9, C-
13 (δC 131.2), C-14 (δC 141.5) and C-24 (δC 138.7). The aromatic methine resonance
CH-26[28] integrated for two proton equivalents in the 1H NMR which indicated the
presence of symmetry in an aromatic ring. The carbon resonances of the aromatic
methines C-25[29] and C-26[28] were also almost twice the intensity of the other aromatic
methines signals. Though the intensity of signals in the 13C NMR are not always a
reliable indication of the number of carbons in the chemical environment this along with
the information from the 1H NMR spectra supports the assumption of symmetry in an
aromatic ring and suggests there are actually seven aromatic methines with two sets of
overlapping resonances, CH-25[29] and CH-26[28].53 HMBC correlations observed from
H-11 to C-8, C-9, C-13 and C-14 and from H-12 to C-8, C-9, C-11 and C-14, suggested
that C-8, C-9, CH-11, CH-12, C-13 and C-14 formed one of the aromatic rings (ring
A, Figure 3.15) leaving the resonances C-24, CH-25[29], CH-26[28] and CH-27 to form
aromatic ring B (Figure 3.18).
The four non-protonated carbons of aromatic ring A suggested it was a tetra-substituted
aromatic ring. Methines CH-11 and CH-12 were placed ortho to each other as both
resonances appeared as doublets in the 1H NMR spectrum with a coupling constant of
8.2 Hz.53 HMBC correlations observed from H-11 and H-12 defined the connectivity of
ring A. Strong HMBC correlations were observed from H-11 to C-13 and C-8, indicating
three-bond connectivity, as well as weak HMBC correlations to C-9 indicating two-bond
connectivity.53 The other aromatic methine, H-12, showed strong HMBC correlations to
C-9 and C-14 which indicated three-bond connectivity, a weak HMBC correlation was
also observed from H-12 to C-11 again indicating two-bond connectivity (Figure 3.15).53
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Figure 3.15. Aromatic ring A of oxeatamide E (27).
Methyl H3-17 (δH 1.52; δC 15.4) appeared as doublet in the
1H NMR, which indicated that
it was adjacent to a methine. COSY correlations observed between H-7 (δH 4.69; δC 40.8)
and H3-17 suggested that CH3-17 was attached to methine CH-7. Correlations observed
from H-7 and H3-17, to the carbonyl resonance C-6 (δC 176.8) in the HMBC spectrum
suggested that C-6 and C-7 were adjacent.
The substitution pattern of aromatic ring A was again assigned on the basis of HMBC
correlations observed to and from positions of the ring as depicted in Figure 3.16. The
cyclohexane ring was attached to C-9 and placed ortho to methine CH-11 based on HMBC
correlations observed from H-11 to C-10, H-5b to C-9 and H3-20 to C-9. The substitution
of C-7 at C-8 of aromatic ring A was assigned based on HMBC correlations from H-7
and H3-17 to the aromatic non-protonated carbon resonance C-8.
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Figure 3.16. Placement of aromatic substituents of aromatic ring A of
oxeatamide E (27).
HMBC correlations observed from H-11 and H-12 to C-16 (δC 168.4) were again used to
position the lactam carbonyl C-16 adjacent to aromatic ring A resonance C-13. Similarly,
methine CH2-15 (δH 4.38, 4.21; δC 50.3) was assigned adjacent to C-14 based on HMBC
correlations from H2-15 to C-14 and a weak correlation observed betwenn H2-15 and C-8.
HMBC correlations were also observed from H2-15 to C-13 and C-16. These correlations,
42
as well as the chemical shift for C-16 being consistent with that of a lactam carbonyl and
the 1JCH of 143 Hz for CH2-15, which is typical for a carbon adjacent to nitrogen, again
suggested the presence of a lactam.53
The NMR data for the aromatic ring and lactam of oxeatamide E (27) was compared to
that for oxeatamide A (21)41 and D (26) and was consistent with the placement of the
lactam carbonyl adjacent to C-13.
Similarly to oxeatamide D (26) the carbon skeleton of the oxeatamide backbone (32)
was established, leaving C8H9 as well as hydroxyl (an oxygen and exchangeable proton)
unaccounted for. As the carbon resonance of carbonyl C-6 was typical of a carboxylic
acid,53 it was again assumed that the hydroxyl was attached to C-6. The carboxylic acid
functionality at C-6 was once again consistent with the known oxeatamides,53 and the
need for an acidic mobile phase during HPLC separation (Scheme 3.2).
COSY correlations, depicted in Figure 3.17, were observed between methylene protons
H2-22 (δH 3.83, 3.74; δC 44.1) and H2-23 (δH 2.94; δC 34.7) suggesting CH2-22 and
CH2-23 were adjacent. Methylene CH2-22 had a
1JCH of 140 Hz consistent for a carbon
adjacent to nitrogen,53 suggesting CH2-22 was adjacent to N-21. This was supported by
HMBC correlations observed from H2-22 to C-15 and C-16. HMBC correlations observed
from H2-22 and H2-23 to C-24 indicated that CH2-23 was adjacent to C-24 which was part
of the previously identified aromatic ring B.
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Figure 3.17. COSY and HMBC correlations establishing the attachment and
connectivity of C-22 to C-24 of oxeatamide E (27).
Aromatic ring B appeared to have symmetry as only four distinct resonances were
observed in the 13C NMR. Analysis of the 1H, 13C and HSQC determined that methine
resonances CH-25 and CH-26 also accounted for CH-29 and CH-28 respectively. This
43
was supported by the pseudo 1JCH HMBC correlations observed from H-25 to C-25 and
H-26 to C-26 which were actually correlations from H-25 to C-29, H-29 to C-25, H-26 to
C-28, and H-28 to C-26. The CH-27 resonance accounted for only one methine and was
thus placed para to the non-protonated aromatic carbon C-24. Correlations observed in
the HMBC spectrum to C-23 from H-25[29] and from H-23 to C-25[29] in conjunction
with the doublet observed in the 1H NMR for H-25[29] indicated aromatic methines C-
25[29] were adjacent to the attachment point C-24 and a methine. The placement of C-24,
CH-25[29] and CH-27 as well as HMBC and COSY correlations helped to determine that
CH-26[28], a triplet in the 1H NMR spectrum, was adjacent to both CH-25[29] and CH-
27 (Figure 3.18). The amnio acid origin of the N-21 to C-29 fragment, decarboxylated
phenylalanine, is discussed in Section 3.6.2.
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Figure 3.18. COSY and key HMBC correlations establishing aromatic ring B of
oxeatamide E (27).
With the oxeatamide backbone accounting for the majority of the determined molecular
formula, C28H35NO3, of 27, the remaining ethyl phenyl fragment was found to be attached
to the lactam nitrogen N-21. Therefore the structure of oxeatamide E is given as 27 with
NMR data presented in Table 3.5. Due to the similarity in chemical shifts and coupling
constants the configuration of oxeatamide E (27) was assumed to be analogous to that
established for oxeatamide D (26), previously discussed in Section 3.4.2.
44
Ta
bl
e
3.
5.
13
C
(1
50
M
H
z)
,1
H
(6
00
M
H
z)
N
M
R
da
ta
(C
D
C
l 3
)f
or
ox
ea
ta
m
id
e
E
(2
7)
.
N
O
O
HO
1 4
5 181
7
19
6
7
8
11
12
16 15
1020
24
25
26
27
27
13
C
1 H
C
O
SY
H
M
B
C
Po
si
tio
n
δ
(p
pm
)
m
ul
t
J
(H
z)
δ
(p
pm
)
m
ul
t
1
J C
H
(H
z)
(1
H
to
13
C
)
1a
40
.9
C
H
2
12
6
2.
34
br
d
14
.2
1b
,2
a,
2b
,5
a,
20
1b
12
6
1.
46
m
1a
,2
a,
2b
2a
20
.0
C
H
2
12
3
1.
81
m
1a
,1
b,
2b
,3
a,
3b
,2
0
2b
12
3
1.
66
m
1a
,1
b,
2a
,3
a,
3b
,2
0
1,
3,
4
3a
39
.6
C
H
2
12
6
1.
31
m
2a
,2
b,
3b
1,
2,
4,
5,
18
,1
9
3b
12
6
1.
29
m
2a
,2
b,
3a
1,
2,
4,
5,
18
,1
9
4
31
.7
C
5a
50
.7
C
H
2
12
4
2.
03
d
14
1a
,5
b
1,
4,
10
,2
0
5b
12
4
1.
50
br
s
5a
1,
4,
9,
10
,2
0
6
17
6.
8
C
7
40
.8
C
H
11
9
4.
69
q
7.
3
17
6,
8,
9,
14
,1
7
8
13
5.
1
C
9
15
0.
5
C
10
39
.7
C
11
12
7.
5
C
H
16
0
7.
59
d
8.
2
12
8,
9* ,
10
,1
3,
14
* ,1
6*
12
12
2.
0
C
H
16
6
7.
67
d
8.
2
11
8* ,
9,
11
* ,1
4,
16
13
13
1.
2
C
14
14
1.
5
C
15
a
50
.3
C
H
2
14
3
4.
14
d
16
.9
15
b
14
,1
6,
8* ,
9* ,
13
*
15
b
14
2
4.
01
16
.9
15
a
8* ,
9* ,
13
* ,1
4,
16
16
16
8.
4
C
17
15
.4
C
H
3
12
7
1.
52
d
7.
2
7
6,
7,
8
18
27
.1
C
H
3
12
4
0.
38
s
3,
4,
5,
19
19
33
.0
C
H
3
12
2
0.
91
s
3,
4,
5,
18
20
32
.8
C
H
3
12
5
1.
44
s
1a
,2
a,
2b
1,
5,
9
10
22
a
44
.1
C
H
2
14
0
3.
83
dt
14
.1
,7
.1
22
b,
23
15
,1
6,
23
,2
4
22
b
14
0
3.
74
dt
14
.1
,7
.3
22
a,
23
15
,1
6,
23
,2
4
23
34
.7
C
H
2
12
8
2.
94
m
22
a,
22
b,
25
[2
9]
*
22
,2
4,
25
[2
9]
24
13
8.
7
C
25
[2
9]
12
8.
8
C
H
15
7
7.
20
d
7.
6
26
[2
8]
,2
7
23
,2
4* ,
25
[2
9]
,2
6[
28
],
27
26
[2
8]
12
8.
6
C
H
16
1
7.
25
t
7.
1
25
[2
9]
,2
7
24
,2
5[
29
],
26
[2
8]
,2
7*
27
12
6.
5
C
H
16
1
7.
19
t
6.
8
25
[2
9]
,2
6[
28
]
25
[2
9]
,2
6[
28
]
*W
ea
k
co
rr
el
at
io
ns
.
45
3.4.4 Oxeatamide F
The positive ion HRESIMS analysis of oxeatamide F (28) showed an [M + Na]+
pseudomolecular ion at m/z 422.2669 revealing the molecular formula of C25H37NO3,
(∆ 0.5 ppm), which required eight double bond equivalents. The 13C NMR spectrum
contained 22 resonances, which along with the three other resonances observed in the
HSQC and/or HMBC spectra was consistent with the formula. Integration of the 1H NMR
spectrum revealed 36 protons, suggesting one exchangeable proton. Initial analysis of the
13C and multiplicity-edited HSQC spectra (Table 3.6) revealed 17 protonated carbons, six
methyls, seven methylenes and four methines leaving eight non-protonated carbons. A
carboxylic acid/ester carbonyl C-6 (δC 176.3), an amide/lactam carbonyl C-16 (δC 168.6)
and six aromatic resonances— C-8 (δC 134.4) C-9 (δC 150.4), CH-11 (δH 7.61; δC 127.6),
CH-12 (δH 7.68; δC 122.4), C-13 (δC 131.6) and C-14 (δC 141.3)— were again tentatively
assigned due to their typical chemical shift values.53 The aromatic ring system along
with the two carbonyl groups accounted for six double bond equivalents suggesting the
compound contained two other ring systems.
In a similar fashion to oxeatamide D (26) and E (27) COSY correlations led to the
establishment of a methylene chain CH2-1 to CH2-3. HMBC correlations attached C-
10 to C-1, C-5 and C-20. Unlike 26 and 27 an HMBC correlation was observed from
H-1a to C-10. Likewise, the gem-dimethyl moiety, CH3-18 and CH3-19, was attached
to C-4 and placed adjacent to CH2-3 and CH2-5 using COSY and HMBC correlations
forming the cyclohexane ring (Figure 3.19).
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CH3
CH3H3C
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18 19
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H
H
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Figure 3.19. COSY and key HMBC correlations establishing connectivity of
cyclohexane ring of oxeatamide F (28).
Once again the coupling constant of 8.2 Hz, as well as a COSY correlation were used
to establish the ortho positioning of the aromatic methine protons.53 Again correlations
46
observed in the HMBC spectrum from the aromatic methine protons H-11 and H-12 were
used to establish the connectivity of the tetra-substituted aromatic ring (Figure 3.20).
COSY
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11
12
13
14 Weak HMBC
Figure 3.20. Aromatic ring connectivity of oxeatamide F (28).
Similarly, the methyl CH3-17 was placed adjacent to methine CH-7 using COSY and
HMBC correlations. HMBC correlations were again used to establish the carbonyl C-6
was adjacent to C-7 (Figure 3.21).
7
6
17
COSY
HMBC
H
H3C
O
X
Figure 3.21. Connectivity around carbonyl C-6 of oxeatamide F (28).
In a similar fashion to 26 and 27 the substitution pattern of the aromatic ring was assigned
based on correlations observed in the HMBC spectrum. The 1,3,3-trimethyl cyclohexane
ring was placed ortho to H-11 and attached to C-9. The methine CH-7 was positioned
adjacent to C-8. The substituents at C-13 and C-14 were also established through HMBC
correlations. The carbonyl C-16 was positioned adjacent to C-13 and the methylene C-
15 was placed adjacent to C-14. Similarly CH2-15 had a
1JCH of 142 Hz, consistent for
a carbon attached to nitrogen,53 and the chemical shift of C-16 was consistent with a
carbonyl of a lactam again indicating the presence of a γ-lactam ring (Figure 3.22).
Thus the elucidation of the carbon skeleton of the oxeatamide backbone (32) was
complete leaving a C5H11 fragment as well as an exchangeable proton and oxygen to
be assigned. The chemical shift of the C-6 carbonyl was again typical of a carboxylic
acid,53 and therefore the oxygen and exchangeable proton were once again assumed to
be attached to C-6. Likewise the proposed carboxylic acid functionality at C-6 was
consistent with the chromatographic behaviour observed (Scheme 3.2) and the known
47
oxeatamides.41
Methyl CH3-25 appeared as a triplet in the
1H NMR indicating it was attached to a
methylene. COSY correlations observed between H3-25 and H2-24 established that C-25
was adjacent to C-24. HMBC correlations from H3-25 to C-24 as well as methine C-23
were also observed, suggesting that C-24 and C-23 were adjacent. HMBC correlations
were also observed from H2-24 to C-23. COSY correlations observed between H-23 and
methylene H2-22 placed them adjacent to each other. Methyl H2-26 appeared as a doublet
in the 1H NMR indicating it was attached to a methine, HMBC correlations from it to
C-23 as well as C-22 and C-24 were used to attach it to C-23. CH2-22 (δH 3.42, 3.39;
δC 48.5) had a 1JCH value of 137 Hz suggesting that it was adjacent to a nitrogen,53 this
in conjunction with HMBC correlations observed from H2-22 to C-15 and C-16 indicated
that CH2-22 was adjacent to N-21. Thus completing the elucidation of the C5H11 fragment
remaining (Figure 3.23). This fragment is proposed to arise from a reaction of a terpene
precursor and amino acid isoleucine, which is discussed later in Section 3.6.2.
Therefore the structure of oxeatamide F is given as 28 with NMR data presented in Table
3.6. The 7R* 10S* relative configuration is assumed, based on that previously assigned
for oxeatamide D and the other known oxeatamides.41
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Figure 3.22. Placement of aromatic substituents of oxeatamide F (28).
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Figure 3.23. COSY and key HMBC correlations establishing the attachment and
connectivity of C-22 to C-26 fragment of oxeatamide F (28).
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3.4.5 Oxeatamide G
Observation of the the positive ion mode HRESIMS pseudomolecular ion [M + Na]+
m/z 422.2670, enabled the formula of oxeatamide G (29) to be established as C25H37NO3,
∆ 0.2 ppm, requiring eight double bond equivalents. The molecular formula of 29
was identical to oxeatamide F (28) establishing them as structural isomers. A notable
difference was the upfield methyl signals observed in the 13C NMR for C-25 and C-26
of 28 appeared to be shifted downfield in 29. The 13C NMR spectrum of 29 contained
22 resonances, this in conjunction with the three other resonances observed in the HSQC
and/or the HMBC was consistent with its molecular formula. Thirty-six protons were
accounted for in the 1H NMR spectrum, suggesting one exchangeable proton. Preliminary
analysis of the 13C and multiplicity-edited HSQC NMR spectra revealed 17 protonated
carbons, six methyls, seven methylenes and four methines which left eight non-protonated
carbons. Analogous with the other oxeatamides, a carboxylic acid/ester carbonyl C-6
(δC 176.8), an amide/lactam carbonyl C-16 (δC 168.0) and six aromatic resonances, C-8
(δC 134.7) C-9 (δC 150.3), CH-11 (δH 7.59; δC 127.6), CH-12 (δH 7.65; δC 122.3), C-13
(δC 131.7) and C-14 (δC 141.3), were assigned due to their typical chemical shift values
leaving two double bond equivalents unaccounted for, indicating the compound contained
two other ring systems.
Again, COSY and HMBC correlations were used to construct a 1,3,3-trimethyl cyclo-
hexane ring, consistent with the other oxeatamides. Likewise, correlations observed in
the HMBC spectrum from the aromatic methine protons H-11 and H-12 were used to
establish the connectivity of the tetra-substituted aromatic ring. The C-6, C-7 and C-17
fragment was similarly established using COSY and HMBC correlations. Once again the
substitution pattern of the aromatic ring was assigned based on correlations observed
in the HMBC spectrum. The lactam ring was established using HMBC correlations,
completing the oxeatamide diterpene backbone.
As before these substructures accounted for C20H26NO3 leaving C5H11 as the side chain
of N-21.
51
Methyls C-25 and C-26 had almost identical chemical shifts, and both appeared as
doublets in the 1H NMR indicating they were attached to a methine. HMBC correlations
from H3-25 and H3-26 to each other as well as to methine C-24, indicated that C-24
was adjacent to C-25 and C-26. HMBC correlations were also observed from H-24, H3-
25 and H3-26 to methylene C-23, placing C-24 adjacent to C-23. COSY correlations
between C-23 and methylene C-22, established they were adjacent carbons. Methylene
CH2-22 had a
1JCH value of 143 Hz, which in conjunction with the methylene’s downfield
chemical shift, again suggested that CH2-22 was adjacent to nitrogen.
53 In conjunction
with HMBC correlations observed from H2-22 to C-15 and C-16 this indicated that CH2-
22 was adjacent to N-21, therefore completing the structure elucidation of oxeatamide G
(29) which is depicted in Figure 3.24.
HMBCCOOH
N
O
COSY
15
16
21
CH3
CH3
H
H H
H
H
22
23
24
25
26
Figure 3.24. COSY and key HMBC correlations establishing the attachment and
connectivity of C-22 to C-26 fragment of oxeatamide G (29).
A 3-methyl butyl moiety, possibly originating from decarboxylated leucine (discussed
later in Section 3.6.2), was found to be attached to the lactam nitrogen N-21 of the
oxeatamide backbone (32). The structure of oxeatamide G is given as 29 with NMR
data presented in Table 3.7. The relative configuration is assumed to be analogous to the
oxeatamide D (26).
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3.4.6 Methylation of Oxeatamide G
A derivatisation reaction of oxeatamide G (29) was performed to confirm the presence
of the carboxylic acid moiety at C-6. A small amount of 29, approximately 100 µg, was
methylated to 33 using TMSCHN2. The reaction went to completion and a new methyl
signal was seen at 3.64 ppm in the 1H NMR. An HMBC correlation was observed from
this new methyl resonance to carbonyl resonance C-6 (δC 174.5), this in conjunction with
the correlation observed from methine H-7, (δH 1.63 ppm) to the same carbonyl resonance
indicated that the new methyl resonance was attached through an oxygen to carbonyl C-6.
Unfortunately, during the methylation process the sample was contaminated with plas-
ticsizers of unknown origin. The plasticsizers co-eluted with 33 off PSDVB and
further attempts at separation were unsuccessful. To confirm the presence of the
methylated product the sample was submitted for MS. The pseudo-molecular ion peak
[M + H]+observed at m/z 414.3005 revealed the molecular formula C26H39NO3,(∆ 0.3
ppm) indicating the methylation was successful, thus proving that carbonyl C-6 is in
fact a carboxylic acid. A carboxylic acid moiety at C-6 is consistent with the known
oxeatamides,41 as well as the chromatographic behaviour observed (depicted in Schemes
3.1 and 3.2).
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3.4.7 Oxeatamide C
The molecular formula C22H32N2O3 for oxeatamide C (25) was determined from a
HRESIMS of the [M + Na]+ pseudo-molecular ion at m/z 395.2318 (∆ 0.5 ppm),
requiring eight double bond equivalents. Like oxeatamide B (24) and unlike the other
known oxeatamides,41 25 was only sparingly soluble in CDCl3 and all NMR data were
obtained in d6-DMSO. The use of d6-DMSO revealed the three exchangeable protons
as a broad signal centred around 4 ppm. The 1H NMR spectrum accounted for all 32
protons. Only 13 resonances were observed in the 13C NMR spectrum, in part due
to overlap with the d6-DMSO residual solvent signal, these resonances in conjunction
with the nine other carbon resonances observed in the HSQC and/or HMBC spectra
was consistent with the formula. Initial analysis of the 13C and multiplicity-edited
HSQC NMR spectra (Table 3.8) revealed 14 protonated carbons leaving eight quaternary
carbons. Several carbon resonances were tentativily assigned including a carboxylic
acid/ester carbonyl (δC 175.1), an amide/lactam carbonyl (δC 167.1) and six aromatic
resonances (δC 122.2, 127.5, 131.6, 136.7, 142.4, 150.0).53 This accounted for six of the
double bond equivalents.
In a similar fashion to the other oxeatamides COSY and HMBC correlations were used to
construct the oxeatamide backbone, leaving C2H6N as the lactam substituent.
C-22 had a 1JCH value of 140 Hz suggesting that it was adjacent to nitrogen, this in
conjunction with HMBC correlations observed from H2-22 to C-16 indicated that C-
22 was adjacent to N-21. COSY correlations were observed between H2-22 and H2-23
suggesting the two methylenes were adjacent. C-23 had a 1JCH value of 137 Hz suggesting
it was also adjacent to a nitrogen, N-24. With all the carbons assigned this suggested
that N-24 was a primary amine with two exchangeable protons attached (Figure 3.25).
This left one exchangeable proton and oxygen unaccounted for. The proposed carboxylic
acid functionality at C-6 was consistent with the chromatographic behaviour observed
(Scheme 3.1) and the known oxeatamides. Therefore the structure of oxeatamide C is
given as 25 with NMR data presented in Table 3.8, the relative configuration is assumed
to be 7R* 10S*.
55
HMBCCOOH
N
O
COSY
15
16
21
NH2
H H
H
H
22
23
24
Figure 3.25. COSY and key HMBC correlations establishing the attachment and
connectivity of C-22 to N-24 fragment of oxeatamide C (25).
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3.4.8 Biological activity of oxeatamides
The cytotoxicity of oxeatamides C to G (25—29) against human cancer cell lines has
undergone preliminary investigation. An MTT assay on HL-60 cells was run. The
oxeatamides were found to be moderately cytotoxic with IC50 values in the 10 to 50
micromolar range.56 This was consistent with the activity of the known oxeatamides.41
The known oxeatamides also exhibited some promising antimycobacterial activity.41
Based on this knowledge, oxeatamides C to G have been submitted for antibacterial
testing to the School of Biological Sciences at VUW, however the results are still pending.
3.4.9 Summary
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Five new oxeatamides were isolated from Darwinella oxeata in this study. All shared
the oxeatamide backbone (34), and differed only in the lactam substituent. The lactam
substiuents were found to be ethyl amine, 2-methyl propyl, ethyl benzyl, 2-methyl butyl
and 3-methyl butyl for oxeatamides C (25), D (26), E (27), F (28) and G (29), respectively.
The proposed amino acid origin of the lactam substituents of the oxeatamides is discussed
later in Section 3.6.3.
The relative configuration of oxeatamide D (26) was established as 7R*, 10S* based
on analysis of NMR data obtained in CD3OD. The configuration of the other new
oxeatamides is thought to be analogous to that proposed for oxeatamide D.
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Oxeatamide G (29) was methylated to 33 using TMS diazomethane to prove the car-
boxylic acid functionality of the new oxeatamides proposed in the structure elucidation.
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3.5 Spongian Diterpenoids
Over 150 spongian and rearranged spongian diterpenoids had been isolated from the
sponge orders Dendroceratida and Dictyoceratida up to 2004.21 Compounds with the
spongian diterpene backbone (35) are often highly oxygenated in a variety of positions,
many have undergone a carbon skeleton rearrangement. All of the compounds isolated
from Darwinella have a specific rearranged spongian diterpenoid backbone known as the
the aplysulphurane backbone (16).41,48,49
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The proposed biogenesis of the aplysulphrane backbone (16) from the spongian diterpene
backbone (35) involves the Wagner-Meerwin rearrangent of the C-17 methyl from C-8 to
adjacent C-7, followed by the oxidative cleavage of the C-5/C-6 bond (Scheme 3.3).57
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Scheme 3.3. Proposed biogenesis of the aplysulphurane (16) backbone from the
spongian diterpene backbone (35) adapted from Keyzers et al.57
The first reported aplysulphurane was aplysulphurin (17) by Karuso et al. in 1984.48
Aplysulphurin along with the other aplysulphuranes (16) isolated from Darwinlela oxeata
— including the tetrahydroaplysulphurins (18–20) and the nitrogenous oxeatamides (21–
24) — have been discussed earlier in Section 3.2. In 1987, Molinski and Faulkner reported
the isolation of membranolide (36) from the Antarctic sponge Dendrilla membranosa.55
Tischler and Andersen then reported the isolation of cadlinolides A (37) and B (38), from
Aplysilla glacialis in 1991.58 Membranolides B (39), C (30) and D (31) were isolated by
Ankisetty et al. from D. membranosa in 2004.52 The membranolides possessed modest
antibacterial activity when tested.52 Also in 2004 Keyzers et al. reported the isolation
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of five new aplysulphuranes from Chelonaplysilla violacea: cadlinolide C (40) and D
(41), pourewic acid (42), 15-methoxypourewic acid (43) and methyl pourewate (44).39,57
Cadlinolide C (40), pourewic acid (42) and methyl pourewate (44) exhibited moderate
activity in a neutrophil superoxide anti-inflammatory assay.39,57 Simultaneously with
Keyzers et al. Diaz-Marrero et al. reported the isolation of cadlinolide C (40) and
pourewic acid (42), as well as compound 45.51
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3.6 Nitrogenous Terpenoids
A review of the literature establishes that many marine nitrogenous terpenes including
isocyanides, isothiocyanates, thiocyanates, dichloroimines and formamides have been
reported where the origin of nitrogen was proposed to be from an inorganic source.59
There are also other known nitrogenous terpenes, such as steroidal compounds.23–29 The
focus was narrowed to the more pertinent terpenes with nitrogens of proposed amino acid
origin.
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3.6.1 Nitrogenous Teprpenes of Proposed Amino Acid Origin
Many examples of terpenes with nitrogens of proposed amino acid origin have been
identified, including the nitrogenous spongian diterpenes discussed in Section 3.6.2, as
well as some nitrogenous sesquiterpenoids, such as pyrodysinoic acid (46) isolated from
the sponge Dysidea sp. 60 and many sesterterpenoid examples. Molliorin A (47) appears
to be the first marine example of a nitrogenous terpene with nitrogen of proposed amino
acid origin to be isolated. Molliorin A (47), a nitrogenous scalarane sesterterpene, was
reported from the sponge Cacospongia mollior in 1977 by Cafieri et al.61 The group
continued to work on the same sponge and isolated four more nitrogenous terpenes
molliorins B (48), C (49), D (50) and E (51) between 1977 and 1979.62–64 All the
molliorins are thought to have nitrogens of amino acid origin (isoleucine, ornithine,
valine, phenylalanine and glycine for molliorins A to E, respectively). Ornithine is
an amino acid with two primary amine functionalities which is not involved in protein
synthesis. It results from the action of the enzyme arginase on amino acid arginine and is
a product of the urea cycle.65
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Sarcotragins A (52) and B (53), nitrogenous trisnorsesterterpenes, were isolated from the
sponge Sarcotragus sp. by Shin et al. in 2001.66 At the time of isolation, the trisnorsester-
terpene portion of the sacrotragins was, to their knowledge, an unprecedented structural
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group amongst sponge metabolites.66 In 2002, four more nitrogenous sesterterpenes
(sarcotrines A (54), B (55), C (56) and D (57)) were isolated from Sarcotragus sp. by
Liu et al.67 They suggested that it was possible the sarcotragins and sarcotrines shared the
same precursor and that the sarcotragins were degradation products of the sarcotrines.67
They also observed degradation of 54, 55 and 56 on standing to the C-21 epimers 58,
59 and 60, respectively.67 Another four nitrogenous sesterterpenes, sacrotrine E (61),
isosarcotrine E (62), sarcotrine F (63) and isosarcotrine F (64), isolated from Sarcotragus
sp. were reported by Liu et al. in the following year (2003).60
3.6.2 Nitrogenous Spongian Diterpenoids
Nitrogenous spongian diterpenes are rare, with only eight reported; the oxeatamides, the
spongolactams and haumanamide (66).41,68,69 All examples have a lactam at ring D. The
proposed source of the lactam nitrogen and alkyl side chain attached to the nitrogen
is of amino acid origin. Pham et al. reported the isolation of the nitrogenous terpene
haumanamide (66), from the sponge Spongia sp. in 1992.68 More recently, spongolactam
A (67), B (68) and C (69) were isolated from Spongia sp. in 2007.69 Exhibiting the same
terpene skeleton as haumanamide (66) the spongolactams have different alkyl side chains
attached to the lactam nitrogen. Spongiolactams A (67) and B (68) are structural isomers
differing only in the placement of the lactam carbonyl, similar to oxeatamide A (21) and
iso-oxeatamide A (23). The spongolactams have shown promising activity as farensyl
transferase inhibitors.69
3.6.3 Proposed Biogenesis of Terpenes with Nitrogens of Proposed
Amino Acid Origin
In 1999, Sayed et al. reported the feeding of the natural product palinurin (70) (which had
been previously isolated from the sponges Ircinia echinata and Ircinia variabillis) to the
fungus Cunninghamella sp.. Palinurin (70), a furanosesterterpene similar to the sarcotins,
was transformed by the fungus to the pyrrolosesterterpenes palinurines A (71) and B (72).
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Their proposed biogenesis pathway for the N-substituted γ-lactam involves the furan of
palinurin (70) reacting with a decarboxylated serine (Scheme 3.4).70
In the case of palinurin (70) the furan oxygen is adjacent to two accessible oxy-methine
carbons. Both of the electron deficient methines are susceptible to the nucleophilic
addition of amino acid derivatives leading to structural isomers of the lactam as seen
in palinurine A (71) and B (72) and several other examples (Table 3.9).
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Pyrodysinoic acid (46), the sarcotragins, the sarcotrines, haumanamide (66), the spongo-
lactams and the oxeatamides are all thought to arise from the reaction of a furan precursor
and an amino acid derivative in a similar manner to that proposed for the reaction of
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Scheme 3.4. Biogenesis of N-substituted lactams from furan precursors,
proposed by El Sayed et al.70
palinurin (70) with decarboxylated serine (Scheme 3.4).70 For many of these compounds
the proposed furan precursor is a known natural product. In the majority of cases, the
amino acid derivate is decarboxylated with the notable exception of glycine. Enzyme
mediated amino acid decarboxylation is a common phenomenon and specific carboxy-
lyase enzymes (EC 4.1.1) have been identified for different amino acid residues. For
example the enzyme responsible for the decarboxylation of phenylananine is aromatic-
L-amino acid carboxy-lyase (EC 4.1.1.28) whilst L-valine carboxy-lyase (EC 4.1.1.14) is
known to decarboxylate valine and leucine.65
It is also possible that the biogenesis pathway of the N-substituted γ-lactams involves the
initial oxidation of a furan precursor by 1O2 as proposed in Scheme 3.5.
The proposed biogenesis of pyrodysinoic acid (46) involves the in vivo reaction of
furodysinin (73)71 and the amino acid glycine. Sarcotragin A (52) and B (53) are
thought to arise from the reaction of sarcotin J (74) with decarboxylated phenylalanine
and glycine respectively. Most of the sarcotrines with the exception of sarcotrine F (63)
and isosarcotrine F (64) can be directly explained by the reaction of sarcotin A (75) or
episarcotin A (76) with an amino acid derivate (refer to Table 3.9 for specific amino acid
derivatives). As Episarcotin A (76) is the position 21 epimer of sarcotin A (75), it is
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Scheme 3.5. Alternative biogenesis pathway for N-substituted lactams involving 1O2
oxidation of furan precursors.
possible that 76 is a degradation product of 75 as degradation on standing of some of the
sarcotrines to postion 21 epimers has been observed.67 Assuming that sarcotrine F (63)
and isosarcotrine F (64) are also derived from a reaction between a furan precursor and
an amino acid derivative, the logical furan precursor is compound 77.
Pham et al. suggested the lactam nitrogen and the alkyl side chain of haumanamide
(66) could be derived from β-phenylethylamine (decarboxylated phenylalanine).68 They
also reported the isolation of furan spongia-13(16),14-dien-19-oic acid (78) from the
same sponge extract as haumanamide (66).68 One can propose that the biogenesis of
haumanmide (66) and spongiolactam A (67), B (68) and C (69) involves the reaction
of spongia-13(16), 14-dien-19-oic acid (78) with various decarboxylated amino acid
derivatives (refer to Table 3.9 for specific amino acid derivatives).
The pyrroloterpene molliorins (47–51) differ from the majority of nitrogenous terpenes
mentioned which have lactam rings. This may indicate a slightly different biogenesis
pathway. Cafieri et al.61 proposed that the biogenesis of molliorin A (47) involves the
in vivo reaction of the known natural product scalaradial (79)72 with decarboxylated
isoleucine.61 Scalaradial (79) does not posses a furan ring and instead has a dialdehyde
moiety which explains the pyrrole formation rather than the lactam. The reaction of the
dialdehydes of scalaradial (79) with amino acid derivatives is thought to account for the
biogenesis of all of the molliorins (refer to Table 3.9 for specific amino acid derivatives).
Molliorin B (48) is an unusual dimer that can be proposed to arise from the reaction of
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two molecules of 79 with decarboxylated ornithine, a diamine.
The oxeatamides possess a lactam at ring D indicating they may arise from the reaction
of a furan precursor and an amino acid derivative. It is proposed that the hypothetical
furan precursor is compound 80, an aplysulphurane skeleton with a carboxylic acid at
position 6 and a furan at ring D. There are no known aplysulphuranes with a furan at ring
D, however amongst the spongian diterpenes as a whole, 25 of the 154 compounds in the
2006 literature review possess a ring D furan.21 The reaction of 80 with decarboxylated
valine, phenylalanine, isoleucine and leucine, in the same manner as proposed for the
synthesis of palinurine A (71) and B (72) (Scheme 3.4), would result in the formation of
oxeatamides D (26), E (27), F (28) and G (29), respectively.
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The origin of the nitrogenous moiety of oxeatamide C (25) is not immediately obvi-
ous. The other oxeatamides all contain nitrogens of proposed protogenic amino acid
origin. Due to this precedence, 2,3-diaminopropanoic acid and ethylene diamine (the
decarboxylated version of the amino acid) were considered as possible precursors of the
nitrogenous portion of oxeatamide C (25). However, to the best of our knowledge, neither
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of these compounds are involved in any of the major metabolic pathways. Assuming the
biogenesis of 25 is similar to that proposed for the other oxeatamides — the enzymatically
controlled reaction of a furan precursor 80 with an amino acid derivative— we propose
two possible biogenesis pathways for the formation of the lactam of 25 from the amino
acids serine and glycine, respectively.
One of proposed biogenesis pathways for the ethylene diamine precursor involves the
oxidation and subsequent transamination of decarboxylated serine. Decarboxylation of
amino acids is, as previously stated, a relatively common enzmatically controlled phe-
nomenon; the enzyme responsible for the decarboxylation of serine is phosphatidylserine
decarboxylase (EC 4.1.1.65).65 The enzymatic oxidation of decarboxylated serine from
an alcohol to an aldehyde would involve a dehydrogenase enzyme and the corresponding
reduction of NAD+ to NADH. The aldehyde would then react with ammonia and be
converted into an amine via imine formation followed by a reduction involving the
corresponding oxidation of NADH to NAD+.
Alternatively, oxeatamide C (25) could derive from oxeatamide A (21) or a glycine
derivative. This proposed biogenesis pathway involves the enzymatic reduction of
the carboxylic acid functionality of either glycine or 21 to an aldehyde followed by
transamination of the aldehyde to an amine (as described previously). The glycine
derivative would then go on to react with the furan precursor 80 (method described
previously) to form oxeatamide C (25).
Interestingly, no dimer of oxeatamide C (25) was isolated. Theoretically it would be
possible for the terminal amine functionality of 25 to react with another furan precursor
80, in the same manner as that proposed for the biogenesis of the other oxeatamides, to
form a dimer.
A schematic of the proposed biogenesis pathway for the known and new oxeatamides
from a furan precursor 80, is depicted in Scheme 3.6.
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Scheme 3.6. Proposed biogenesis of the oxeatamides.
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Chapter 4
Conclusion
This spectroscopic guided study resulted in the isolation and structure elucidation of five
new and five known rearranged spongian diterpenes of the aplysulphurane class from the
New Zealand marine sponge Darwinella oxeata. Two of the known compounds isolated
from D. oxeata had only previously been reported from the Antarctic marine sponge
Dendrilla membranosa. The new compounds, oxeatamides C to G (25–29) share the
same backbone and oxygenation pattern as the known oxeatamides, previously isolated
from this sponge, and differ only in the lactam side chain. Like the known oxeatamides,
the nitrogenous moiety is thought to be amino acid derived. Thus far six of the twenty
protogenic amino acids have been identified as the likely precursors of the nitrogenous
moiety of the oxeatamides, it is possible that there are more congeners yet to be isolated.
The future isolation of the proposed furan precursor 80 would give further support for the
proposed biogenesis pathway.
The origin of the diamine portion of oxeatamide C (25) is not immediately obvious.
However, it is possible that it arises from a precursor or derivatisation of the amino acids
glycine or serine. Theoretically, the terminal primary amine of 25 could react with a
further furan precursor 80 forming a dimer, analogous to molliorin B (48), though this
was not detected.
Oxeatamides C to G (25–29) were moderately cytotoxic towards HL-60 cell lines
in a MTT assay. Due to the promising activity of the known oxeatamides, the
new oxeatamides were also submitted for testing in antimycobacterial assays. Of
particular interest will be their activity against mycobacteria. Any oxeatamide that
exhibits interesting bioactivity can then compared to the observed activity of the other
oxeatamides, essentially a small array of congeners. This would give insight into the
structure-activity relationship and would provide a useful starting place for potential
synthetic derivatives.
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In order to be useful as pharmaceutical leads the absolute configuration of the oxeatamides
would need to be established. Due to the relatively small amount of oxeatamides isolated
crystal growth was not possible. Thus the absolute configuration would need to be
established through synthetic studies.
The success of both this study and that of Wojnar,41 would justify the investigation of the
non-polar fractions of D. oxeata. Crude analysis of the 1H NMR spectra of these fractions
indicates the presence of structurally related compounds.
Four other New Zealand marine sponges were also briefly investigated, leading to the
isolation of a known compound from Dictyodendrilla dendyi. The unidentified sponges
MNP0996 and MNP1003 displayed promising results in the NMR based screening
protocol and thus warrant further investigation by another researcher.
As in this study, a spectroscopic-guided method can result in the isolation of groups of
structurally related new compounds that can be tested in screening libraries, that are
unbiased by specific biological activity (as in bioassay guided studies). Such groups
of congeners can provide significant insight into structure activity relationships, which
normally would not be possible without synthetic derivatisation.
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Chapter 5
Experimental
5.1 General
NMR spectra were obtained using a Varian DirectDrive spectrometer fitted with a triple
resonance HCN cryogenic probe, operating at 600 MHz for the 1H nucleus and 150 MHz
for the 13C nucleus. Chemical shifts (δ ppm) were referenced to the residual solvent
peak.73 Quantification of the samples was performed by 1H NMR using an internal
CH3NO2 standard (100 µL in 5 mL CDCl3), using the acquisition parameters described
by West.36 High-resolution mass spectra were obtained using a Micromass Q-TOF
Premier mass spectrometer. TLC analysis was performed on Machery-Nagel Alugram
SIL G/UV254 normal-phase silica plates using a mobile phase of 5% MeOH/CH2Cl2
unless otherwise stated. TLC plates were visualized by fluorescence quenching under
UV light or by dipping in a solution of 5% H2SO4/MeOH followed by a solution of 0.1%
vanillin/EtOH then application of heat.
Normal-phase column chromatography was performed using YMC Co. LTD 2,3-di-
hydroxypropoxypropyl derivatised silica gel (DIOL). Reversed-phase column chro-
matography was carried out using Supelco Diaion HP20 or HP20SS poly(styrene
divinylbenzene) (PSDVB) resin. High-pressure liquid chromatography (HPLC) was
performed on using a Ranin Dynamax solvent delivery module with 25 mL pump heads.
UV detection for HPLC runs was obtained with a Varian Prostar 335 Diode Array detector.
Solvents used for HPLC were of HPLC grade quality. All other solvents were glass
distilled. Water was distilled and deionised using a Milli-Q ultrapure water system.
Solvent mixtures are reported as % vol/vol, unless otherwise stated.
The Marine Natural Products Group at VUW collected the Darwinella oxeata, Raspailia
topsenti and Dictyodendrilla dendyi specimens whilst NIWA collected sponge specimens
MNP0996 and MNP1003. All sponge specimens were stored at −18 ◦C until extracted.
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A voucher sample of each specimen was taken and stored in 75% IPA/H2O, at the School
of Chemical and Physical Sciences at VUW.
5.2 Investigation of Darwinella oxeata
5.2.1 Initial fractionation of Darwinella oxeata
The Darwinella oxeata specimen was collected in November 2006, from Archway Bay,
Cape Brett, Northland, New Zealand. Frozen sponge (535 g) was cut into small segments
and extracted with MeOH (2 × 2.5 L) for 24 h. The second then first extracts were
passed through 400 mL of HP20 resin pre-equilibrated in MeOH. The combined eluents
were cyclic loaded∗ onto the column. The column was washed with H2O (1.2 L) and
fractionated with 1.2 L portions of i) 20% Me2CO/H2O (fraction i), ii) 40% Me2CO/H2O
(fraction ii), iii) 60% Me2CO/H2O (fraction iii), iv) 80% Me2CO/H2O (fraction iv) and
v) 100% Me2CO (fraction v). Fractions A to D were each individually back loaded∗ onto
columns packed with 150 mL HP20 pre-equilibrated in H2O for fractions A and B and
pre-equilibrated in MeOH for fractions C and D. The columns were then washed with
H2O (450 mL) and eluted with Me2CO (450 mL). The eluents were then concentrated to
dryness to give 78.7 mg of fraction A, 163.4 mg of fraction B, 247.2 mg of fraction C and
891.5 mg of fraction D. Fraction E was also concentrated to dryness (795.4 mg).
5.2.2 Isolation of oxeatamides A, B and C and iso-oxeatamide A
Fraction (i), from the initial fractionation of Darwinella oxeata (as detailed in Section
5.2.1), was dissolved in a minimum amount of 50% MeOH/CH2Cl2 and loaded on to 1 mL
of DIOL and air-dried. The loaded DIOL was added to the top of a 24 mL DIOL column
pre-equilibrated in CH2Cl2. The column was sequentially eluted with 75 mL fractions
of i) CH2Cl2, ii) 1% MeOH/CH2Cl2, iii) 5% MeOH/CH2Cl2, iv) 10% MeOH/CH2Cl2
∗For a detailed discussion of cyclic loading and back loading, please see Chapter 1, Section 1.4.1.
75
(fraction A), v) 20% MeOH/CH2Cl2 (fraction B) and vi) 50% MeOH/CH2Cl2 (fraction
C). The fractions were concentrated to dryness.
Approximately half of fraction (ii), from the initial fractionation of Darwinella oxeata (as
detailed in Section 5.2.1) (∼82 mg) was dissolved in a minimum of CH2Cl2 and loaded
onto a 25 mL DIOL column pre-equilibrated in CH2Cl2. The column was sequentially
eluted with 75 mL fractions of i) CH2Cl2, ii) 1% MeOH/CH2Cl2, iii) 2% MeOH/CH2Cl2,
iv) 5% MeOH/CH2Cl2, v) 10% MeOH/CH2Cl2 (fraction D), vi) 20% MeOH/CH2Cl2
(fraction E) and vii) 50% MeOH/CH2Cl2. This protocol was repeated with the other
half of fraction (ii).
Fraction A (21.5 mg) and fraction C (17 mg) were combined and dissolved in 1 mL of
MeOH. Five 200 µL samples were then injected onto a semi-preparative (1 cm × 25 cm)
Ranin Microb C18 HPLC column pre-equilibrated with 70% MeOH/0.1 M HCOOH(aq),
with a flow rate of 5 mL/min and UV detection set to wavelengths 245 nm and 280 nm.
The column was then eluted isocratically with 70% MeOH/0.1 M HCOOH(aq). The eluent
between 19.5–23.5 minutes (fraction F) was collected. This fraction was back loaded
onto 2 mL HP20SS column. The column was eluted with 6 mL of MeOH and then
concentrated to dryness. 1H NMR analysis showed fraction F contained oxeatamide A
(21).
Fraction D (42 mg) was dissolved in 1.4 mL of MeOH. Seven 200 µL samples were then
injected onto a semi-preparative (1 cm× 25 cm) C18 HPLC column pre-equilibrated with
70% MeOH/0.1 M HCOOH(aq), with a flow rate of 5 mL/min and UV detection set to
wavelengths 245 nm and 280 nm. The column was then eluted with 70% MeOH/0.1 M
HCOOH(aq). Three fractions eluting between 4.5–8.5 minutes (fraction G), 20.8–23.5
minutes (fraction H) and 24.5–26.5 (fraction I) were collected. These fractions (G, H and
I) were each back loaded onto 2 mL HP20SS columns. The columns were each eluted
with 6 mL of MeOH and then concentrated to dryness. 1H NMR analysis showed that
fraction G contained impure oxeatamide B (24), fraction H contained oxeatamide A (21)
and fraction I contained 2.3 mg of impure iso-oxeatamide A (23).
Fraction B (21.2 mg) and fraction E (34.5 mg) were combined and dissolved in 1 mL of
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MeOH. Five 200 µL samples were then injected onto a semi-preparative (1 cm × 25 cm)
C18 HPLC column pre-equilibrated with 70% MeOH/0.1 M HCOOH(aq) , with a flow rate
of 5 mL/min and UV detection set to wavelengths 245 nm and 280 nm. The column was
then eluted with 70% MeOH/0.1 M HCOOH(aq). The fractions eluted between 7.8–15.4
minutes (fraction J) and 20.2–23.8 minutes (fraction K) were collected. Fractions J and
K were each back loaded onto 2 mL HP20SS columns. The columns were each eluted
with 6 mL of MeOH and then concentrated to dryness. 1H NMR analysis showed that
fraction J contained 0.5 mg of oxeatamide C (25) and fraction K contained oxeatamide A
(21).
Fraction G (5.9 mg) was dissolved in 200 µL of MeOH. The sample was then injected
onto a semi-preparative (1 cm × 25 cm) C18 HPLC column pre-equilibrated with 60%
MeOH/0.1 M HCOOH(aq), with a flow rate of 5 mL/min and UV detection set to
wavelengths 245 nm and 280 nm. The column was then eluted with 60% MeOH/0.1
M HCOOHaq. The fraction eluted between 10.1–14.8 minutes (fraction L) was collected.
Fraction L was back loaded onto a 2 mL HP20SS column. The column was eluted with
6 mL of MeOH and then concentrated to dryness. 1H NMR analysis showed that fraction
L contained 3.1 mg oxeatamide B (24).
Fraction I (5.1 mg) was dissolved in 240 µL of MeOH. Three 80 µL samples were then
injected onto an analytical (0.46 cm × 25 cm) Phenomenex C18 HPLC column pre-
equilibrated with 80% MeOH/0.1 M HCOOH(aq), with a flow rate of 1 mL/min and
UV detection set to wavelengths 245 nm and 280 nm. The column was then eluted
isocratically with 80% MeOH/0.1 M HCOOH(aq). The fraction eluted between 8.2–9.7
minutes (fraction M) was collected. This fraction was backloaded onto a 2 mL HP20SS
column. The column was eluted with 6 mL of MeOH and then concentrated to dryness.
1H NMR analysis showed fraction M contained 2.18 mg of iso-oxeatamide A (23).
Fractions F, H and K were combined to yield 34.2 mg of oxeatamide A (21).
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Oxeatamide A (21)
Amphorphous white solid; all spectroscopic data as previously published.41
Iso-oxeatamide A (23)
Amphorphous white solid; all spectroscopic data as previously published.41
Oxeatamide B (24)
Amphorphous white solid; all spectroscopic data as previously published.41
Oxeatamide C (25)
Amphorphous white solid; [α]20D −60.3 ◦C (c 0.15, MeOH); NMR data see Table 3.8;
HRESIMS, observed m/z 395.2318 [M + Na]+, C22H32N2O3Na requires 395.2316, ∆ 0.5
ppm.
5.2.3 Isolation of oxeatamides D, E, F and G
Approximately one-third of fraction (iii) fraction, from the initial fractionation of
Darwinella oxeata (as detailed in Section 5.2.1) (∼80 mg), was dissolved in the minimum
of CH2Cl2 and loaded onto a 22 mL DIOL column pre-equilibrated in CH2Cl2. The
column was sequentially eluted with 70 mL fractions of i) CH2Cl2 (fraction A), ii) 1%
MeOH/CH2Cl2 (fraction B), iii) 2% MeOH/CH2Cl2, iv) 5% MeOH/CH2Cl2, v) 10%
MeOH/CH2Cl2, vi) 20% MeOH/CH2Cl2 and vii) 50% MeOH/CH2Cl2. This protocol
was repeated with the other two-thirds of fraction (iii).
Fraction A (∼40 mg) was dissolved in minimum of CH2Cl2 and loaded onto a 15 mL
DIOL column pre-equilibrated in CH2Cl2. The column was sequentially eluted with
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90 mL fractions of i) CH2Cl2 (fractions 1–30) and ii) 1% MeOH/CH2Cl2 (fractions 31-
60), followed by a 45 mL fraction of iii) 50% MeOH/CH2Cl2. The fractions were analysed
by TLC and fractions 13–39 were combined to give fraction C and fractions 40–42 were
combined to give fraction D.
Fraction B (14.1 mg) was dissolved in a minimum of CH2Cl2 and loaded onto a 10 mL
DIOL column pre-equilibrated in CH2Cl2. The column was sequentially eluted with
60 mL fractions of i) CH2Cl2 (fractions 1–21) and ii) 1% MeOH/CH2Cl2 (fractions 22–
40), followed by a 30 mL fraction of iii) 50% MeOH/CH2Cl2. The fractions were analysed
by TLC and fractions 25–29 were combined to give fraction E.
Fractions D (3.7 mg) and E were combined and dissolved in 650 µL of MeOH. Thirteen
50 µL samples were then injected onto an analytical (0.46 cm× 25 cm) C18 HPLC column
pre-equilibrated with 80% MeOH/0.1 M HCOOH(aq), with a flow rate of 1 mL/min and
UV detection set to wavelengths 245 nm and 280 nm. The column was then eluted
with 80% MeOH/0.1 M HCOOH(aq). The fractions eluted between 17.2–19.1 minutes
(fraction F), 20.0–22.4 minutes (fraction G), 22.5–24.3 minutes (fraction H) and 24.3–
26.7 (fraction I) were collected. These fractions (F, G, H and I) were back loaded onto
2 mL HP20SS columns. The columns were each eluted with 6 mL of MeOH and then
concentrated to dryness. 1H NMR analysis showed that fraction F contained 0.5 mg of
oxeatamide D (26), fraction G contained 1 mg of oxeatamide E (27), fraction H contained
0.8 mg of oxeatamide F (28) and fraction I contained 0.6 mg of oxeatamide G (29).
Fraction C (∼10 mg) was dissolved in 200 µL of MeOH. Four 50 µL samples were then
injected onto an analytical (0.46 cm × 25 cm) C18 HPLC column pre-equilibrated with
80% MeOH/0.1 M HCOOH(aq), with a flow rate of 1 mL/min and UV detection set to
wavelengths 220 nm and 245 nm. The column was then eluted isocratically with 80%
MeOH/0.1 M HCOOH(aq). The fractions eluted between 16.8–18.9 minutes (fraction J),
19.8–23.3 minutes (fraction K), 23.3–25.5 minutes (fraction L), 25.5–27.1 (fraction M)
and 27.1–28.5 (fraction N) were collected. These fractions (J, K, L, M and N) were each
backloaded onto 2 mL HP20SS columns. The eluents were again diluted two-fold and
passed back through their original columns. The columns were each eluted with 6 mL
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of MeOH and then concentrated to dryness. 1H NMR analysis showed that fraction J
contained membranolide C (30), fraction K contained membranolide D (31), fraction L
oxeatamide E (27), fraction M contained oxeatamide F (28) and fraction N contained of
oxeatamide G (29).
Oxeatamide D (26)
Amphorphous white solid; [α]20D −59.2 ◦C (c 0.2, MeOH); NMR data see Table
3.3; HRESIMS, observed m/z 408.2520 [M + Na]+, C24H35NO3Na requires 408.2515,
∆ 1.2 ppm.
Oxeatamide E (27)
Amphorphous white solid; [α]20D −60.1 ◦C (c 0.17, MeOH); NMR data see Table
3.5; HRESIMS, observed m/z 456.2518 [M + Na]+, C28H35NO3Na requires 456.2515,
∆ 0.7 ppm.
Oxeatamide F (28)
Amphorphous white solid; [α]20D −59.9 ◦C (c 0.19, MeOH); NMR data see Table
3.6; HRESIMS, observed m/z 422.2669 [M + Na]+, C25H37NO3Na requires 422.2671,
∆ 0.5 ppm.
Oxeatamide G (29)
Amphorphous white solid; [α]20D −60.1 ◦C (c 0.2, MeOH); NMR data see Table
3.7; HRESIMS, observed m/z 422.2670 [M + Na]+, C25H37NO3Na requires 422.2671,
∆ 0.2 ppm.
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Membranolide C (30)
Amphorphous white solid; all spectroscopic data as previously published.52
Membranolide D (31)
Amphorphous white solid; all spectroscopic data as previously published.52
5.2.4 Methylation of oxeatamide G
To approximately 120 µg of oxeatamide G (29) in 500 µL of dry MeOH, 2.0 M
TMSCHN2 in dry diethyl ether (5 µL, 10 µmol) was added. The reaction was left under
nitrogen at room temperature for 1 h then quenched with 2% acetic acid and left for 1 h.
The resulting mixture was then back loaded onto a 2 mL HP20SS column. The column
was then washed with 10 mL of H2O and eluted with 10 mL 80% Me2CO/H2O followed
by 10 mL of Me2CO. The Me2CO fraction contained 0.1 mg the methyl ester oxeatamide
G (33).
Methyl ester oxeatamide G (33)
Amphorphous white solid; HRESIMS, observed m/z 414.3005 [M + H]+, C26H40NO3
requires 414.3008, ∆ 0.3 ppm.
5.3 Investigation of Dictyodendrilla dendyi
Dictyodendrilla dendyi was collected on February 2005 from Piercy Island, Cape Brett,
Northland, New Zealand. The frozen sponge (301 g) was cut into small segments
and extracted with MeOH (2 × 1.2 L) for 24 h. The second then first extracts were
passed through 250 mL of HP20 resin pre-equilibrated in MeOH. The combined eluents
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were cyclic loaded onto the column. The column was washed with H2O (750 mL)
and fractionated with 750 mL portions of i) 20% Me2CO/H2O (fraction A), ii) 40%
Me2CO/H2O (fraction B), iii) 60% Me2CO/H2O (fraction C), iv) 80% Me2CO/H2O
(fraction D) and v) 100% Me2CO. The cyclic loading eluent was retained as fraction
E. Fractions A to D were each back loaded onto columns packed with 80 mL HP20; pre-
equilibrated in H2O for fractions A and B and pre-equilibrated in MeOH for fractions C
and D. The columns were then washed with H2O (450 mL) and eluted with Me2CO (450
mL). The eluents were then concentrated to dryness to give 113.4 mg of fraction A, 803.8
mg of fraction B, 493.7mg of fraction C and 527.6 mg of fraction D.
The cyclic loading eluent, fraction E, was saturated with NaCl and passed through a
column packed with 80 mL HP20 pre-equilibrated in H2O. The column was then washed
with H2O (450 mL) and eluted with Me2CO (450 mL) and the eluent concentrated to
dryness. This fraction was then loaded onto 100 mL column of Sephadex G10 and eluted
with H2O into test tubes. All test tubes were concentrated to dryness and all that contained
black residue were combined giving fraction F. Approximately half of fraction F, was
dissolved in 2 mL of 50% MeOH/CH2Cl2 and loaded on to 4 mL of DIOL pre-equilibrated
in CH2Cl2, the eluent was diluted with 2 mL CH2Cl2 and passed back through the column,
the eluent was diluted with 4 mL CH2Cl2 and passed back through the column, the eluent
was diluted with 8 mL CH2Cl2 and passed back through the column finally the eluent
was diluted with 16 mL CH2Cl2 and passed back through the column. The loaded DIOL
column was sequentially eluted with 12 mL fractions of i) CH2Cl2, ii) 5% MeOH/CH2Cl2,
iii) 10% MeOH/CH2Cl2, iv) 20% MeOH/CH2Cl2, v) 30% MeOH/CH2Cl2 (fraction G),
vi) 40% MeOH/CH2Cl2 and vii) 50% MeOH/CH2Cl2. Fraction G was found to contain
5.3 mg of lamellarin θ 4”,4”’- disulfate (14).
Lamellarin θ 4”,4”’- disulfate (14)
Yellow-brown oil; all spectroscopic data as previously published.40
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5.4 Investigation of Raspailia topsenti
Raspailia topsenti was collected in January 2002 from Great Barrier Island, North Island,
New Zealand. The frozen sponge (210 g) was cut into small segments and extracted with
MeOH (2× 800 mL) for 24 h. The second then first extracts were passed through 150 mL
of HP20 resin pre-equilibrated in MeOH. The combined eluents were cyclic loaded onto
the column. The column was washed with H2O (450 mL) and fractionated with 450 mL
portions of i) 40% Me2CO/H2O (fractionA), ii) 60% Me2CO/H2O (fraction B), iii) 80%
Me2CO/H2O (fraction C) and iv) 100% Me2CO. Fractions A to C were each back loaded
onto columns packed with 80 mL HP20 resin; pre-equilibrated in H2O for fraction A and
pre-equilibrated in MeOH for fractions B and C. The columns were then washed with
H2O (250 mL) and eluted with Me2CO (250 mL). The eluents were then concentrated to
dryness to give 135.4 mg of fraction A, 292.2 mg of fraction B and 430.3 mg of fraction
C.
5.5 Investigation of MNP1003
Unidentified sponge, MNP1003, was collected by NIWA in April 2000 from D’Urville
Island, Marlborough Sounds, New Zealand. The frozen sponge (203 g) was cut into small
segments and extracted with MeOH (2 × 1 L) for 24 h. The second then first extracts
were passed through 80 mL of HP20 resin pre-equilibrated in MeOH. The combined
eluents were cyclic loaded onto the column. The column was washed with H2O (250
mL) and fractionated with 250 mL portions of i) 20% Me2CO/H2O (fraction A), ii)
40% Me2CO/H2O (fraction B), iii) 60% Me2CO/H2O (fraction C), iv) 80% Me2CO/H2O
(fraction D) and v) 100% Me2CO. Fractions A to D were each back loaded onto
columns packed with 40 mL HP20 pre-equilibrated in H2O for fractions A and B and
pre-equilibrated in MeOH for fractions C and D. The columns were then washed with
H2O (120 mL) and eluted with Me2CO (120 mL). The eluents were then concentrated to
dryness to give 92.3 mg of fraction A, 14.8 mg of fraction B, 36.6 mg of fraction C and
220 mg of fraction D.
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5.6 Investigation of MNP0996
Unidentified sponge, MNP0996, was collected by NIWA in April 2000 from D’Urville
Island, Marlborough Sounds, New Zealand. The frozen sponge (403 g) was cut into small
segments and extracted with MeOH (2 × 2 L) for 24 h. The second then first extracts
were passed through 150 mL of HP20 resin pre-equilibrated in MeOH. The combined
eluents were cyclic loaded onto the column. The column was washed with H2O (450
mL) and fractionated with 450 mL portions of i) 20% Me2CO/H2O (fraction A), ii)
40% Me2CO/H2O (fraction B), iii) 60% Me2CO/H2O (fraction C), iv) 80% Me2CO/H2O
(fraction D) and v) 100% Me2CO (fraction E). Fractions A to D were each back loaded
onto columns packed with 80 mL HP20 pre-equilibrated in H2O for fractions A and B
and pre-equilibrated in MeOH for fractions C and D. The columns were then washed with
H2O (250 mL) and eluted with Me2CO (250 mL). The eluents were then concentrated to
dryness to give 13.4 mg of fraction A, 22.8 mg of fraction B, 94.5 mg of fraction C and
597.7 mg of fraction D. Fraction E was also concentrated to dryness yielding 998 mg.
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Appendix A
Existing Sponge Screening Protocol∗
Preparation
Equipment Needed (per Screen)
• 1 x Screen column loaded with 80 mL of HP20 equilibrated in distilled MeOH
• 1 x Backloading column loaded with 40 mL of HP20 equilibrated in distilled MeOH
NMR Standard
Prepare a standard of 1,3,5-tribromobenzene in CDCl3 by dissolving 78.9 mg of 1,3,5-
tribromobenzene in 5 mL of CDCl3.
Procedure
1. Voucher Sample Preparation
• Take a voucher specimen of ca. 10 g of sponge material ensuring that both the
ectoderm and the endoderm are represented.
• Label and store the voucher sample in 75% IPA in H2O.
2. Extraction
• Extract ca. 100 g of sponge material in 400 mL of distilled MeOH overnight.
• Filter the first extract and set aside. Re-extract the sponge material (and any
filter paper/celite as necessary) in 400 mL of distilled MeOH overnight.
∗Last updated: 13/11/06
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• Filter the second extract.
• Keep all sponge material (and any filter paper/celite as necessary) until the
screen is complete at which time it may be discarded.
3. Cyclic Loading
• Pass the second extract through the screen column with a flow rate of ca.
10 mL/min.
• Pass the first extract through the screen column with a flow rate of ca.
10 mL/min. Combine the eluent with that of the second extract.
• Dilute the combined eluents with 800 mL of distilled H2O. Pass the diluted
eluents back through the screen column at a flow rate of ca. 10 mL/min.
• Dilute the eluent with 1.6 L of distilled H2O. Pass the diluted eluent back
through the screen column at a flow rate of ca. 10 mL/min.
• The eluent should be kept until the screen is complete at which time it may be
discarded.
4. Elution
• Elute the screen column with 250 mL of distilled H2O at a flow rate of ca.
10 mL/min. The H2O eluent can be discarded immediately.
• Elute the screen column with 250 mL of 30% distilled Me2CO in distilled
H2O (75 mL Me2CO to 175 mL H2O) at a flow rate of ca. 10 mL/min.
• Elute the screen column with 250 mL of 75% distilled Me2CO in distilled
H2O (187.5 mL Me2CO to 62.5 mL H2O) at a flow rate of ca. 10 mL/min.
• Elute the screen column with 250 mL of distilled Me2CO at a flow rate of ca.
10 mL/min.
5. Backloading the 75% Acetone Fraction
• Dilute the 75% Me2CO fraction with 250 mL of distilled H2O. Pass the diluted
eluent through the backloading column at a flow rate of ca. 8 mL/min.
• Dilute the eluent with 500 mL of distilled H2O. Pass the diluted eluent back
through the backloading column at a flow rate of ca. 8 mL/min.
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• The eluent should be kept until the screen is complete at which time it may be
discarded.
• Elute the backloading column with 150 mL of distilled Me2CO.
6. Processing the 75% Acetone Fraction
• Evaporate the Me2CO eluent of the backloading column to dryness and
transfer to a pre-weighed sample vial. Evaporate to dryness and record the
mass.
• Sub-sample approximately 30 mg of material for NMR analysis if necessary.
• Prepare an NMR sample in ca. 700 µL of CD3OD in a 5 mm NMR tube.
• Add 10 µL of the 1,3,5-tribromobenzene standard (representing 507 nmol of
1,3,5-tribromobenzene) to the NMR tube.
7. NMR Analysis of the 75% Acetone Fraction
• Run a 1H spectrum of the sample on the 600 MHz instrument using the
standard Screen1H parameter set. (Experiment time: ca. 4 min)
• Make a note “Standard Added” in the sample text.
• Run a COSY spectrum of the sample using the standard ScreenCOSY
parameter set. (Experiment time: ca. 20 min)
• Run an HSQC spectrum of the sample using the standard ScreenHSQC
parameter set. (Experiment time: ca. 4 h)
• Process appropriately and export HSQC phasefile.
• Add HSQC phasefile to HSQC mask.
• Apply HSQC mask to HSQC phasefile.
8. Assigning Hit Values to the Screen
• Threshold set at 3%.
• Signal strength
– An arbitrary value indicating how the strength of the interesting peaks.
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– Weak – 1. Medium – 2. Strong – 3 (remember to consider the sub-
sampling factor if necessary).
• Number of interesting peaks
– Indicates how many red peaks in the HSQC. Something exhibiting more
than 20 non-masked peaks will score a 10.
• Uniqueness of interesting peaks
– An arbitrary value indicating whether non-masked peaks represent some-
thing interesting (1-10).
• Available mass
– The total mass of the available sponge material (including that used for
the screen) in kg is multiplied by 10 and rounded to the nearest integer. If
more than 1 kg of sponge material is available the score is 10.
• Recollectability
– Collected locally – 3. Collected from Northland – 2. Other – 1.
• Sum all 5 hit values. A score of 20 would be considered average.
9. Backloading the 30% Acetone Fraction
• Dilute the 30% Me2CO fraction with 250 mL of distilled H2O. Pass the diluted
eluent through the backloading column at a flow rate of ca. 8 mL/min.
• Dilute the eluent with 500 mL of distilled H2O. Pass the diluted eluent back
through the backloading column at a flow rate of ca. 8 mL/min.
• The eluent should be kept until the screen is complete at which time it may be
discarded.
• Elute the backloading column with 150 mL of distilled MeOH.
10. Processing the 30% Acetone Fraction
• Evaporate the MeOH eluent of the backloading column to dryness and transfer
to a pre-weighed sample vial. Evaporate to dryness and record the mass.
• Sub-sample approximately 30 mg of material for NMR analysis if necessary.
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• Prepare an NMR sample in ca. 700 µL of CD3OD in a 5 mm NMR tube.
11. NMR Analysis of the 30% Acetone Fraction
• Run a 1H spectrum of the sample on the 600 MHz instrument using the
standard Screen1H parameter set. (Experiment time: ca. 4 min)
12. Processing the 100% Acetone Fraction
• Evaporate the Me2CO eluent of the screen column to dryness and transfer to
a pre-weighed sample vial. Evaporate to dryness and the record mass.
• Sub-sample approximately 30 mg of material for NMR analysis if necessary.
• Prepare an NMR sample in ca. 700 µL of CDCl3 in a 5 mm NMR tube.
13. NMR Analysis of the 100% Acetone Fraction
• Run a 1H spectrum of the sample on the 600 MHz instrument using the
standard Screen1H parameter set. (Experiment time: ca. 4 min)
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Standard NMR Parameter Sets for Screening
Screen1H (Standard Pulse-acquire)
Acquisition: acquisition delay 10 ms
nutation angle 60◦
acquisition time 4 s (38462 complex points)
steady-state scans none
number of transients 64
temperature 20 ◦C
spectral width 14 ppm to −2 ppm
total time ca. 4 min
Processing: fourier number 65536 complex points
weighting none
ScreenCOSY (Absolute Value Gradient COSY)
Acquisition: acquisition delay 2 s
gradient strength 10 G cm−1
gradient duration 1 ms
gradient stabilisation delay 500 µs
number of increments 512
acquisition time 213 ms (1153 complex points)
steady state scans 16
number of transients 1
temperature 20 ◦C
spectral width (F2 & F1) 9 ppm to 0 ppm
total time ca. 20 min
Processing: fourier number (F2 & F1) 2048 complex points
weighting (F2 & F1) sinebell
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ScreenHSQC (Adiabatic Gradient-enhanced HSQC)
Acquisition: steady-state gradient strength 13 G cm−1
steady-state gradient duration 2 ms
acquisition delay 1.5 s
TANGO gradient strength 10 Gcm−1
TANGO gradient duration 2 ms
adiabatic sweep pulse bandwidth 300 ppm
encoding gradient strength 10 Gcm−1
encoding gradient time 4 ms
decoding gradient strength −6 Gcm−1
decoding gradient time 2.4 ms
number of increments 512
acquisition time 213 ms (1153 complex points)
broadband 13C decoupling shape WURST40
broadband 13C decoupling bandwidth 200 ppm
steady state scans 64
number of transients 8
temperature 20 ◦C
spectral width in F2 9 ppm to 0 ppm
spectral width in F1 160 ppm to 0 ppm
1JCH selection 140 Hz
total time ca. 4 h
Processing: fourier number in F2 2048 complex points
fourier number in F1 1024 complex points
weighting (F2 & F1) gaussian
91
Appendix B
Oxeatamide D
1H NMR spectrum of oxeatamide D (26) (600 MHz, CDCl3)
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13C NMR spectrum of oxeatamide D (26) (150 MHz, CDCl3)
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COSY NMR spectrum of oxeatamide D (26) (600 MHz, CDCl3)
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HSQC NMR spectrum of oxeatamide D (26) (600 MHz, CDCl3)
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HMBC NMR spectrum of oxeatamide D (26) (600 MHz, CDCl3)
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Appendix C
Oxeatamide E
1H NMR spectrum of oxeatamide E (27) (600 MHz, CDCl3)
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13C NMR spectrum of oxeatamide E (27) (150 MHz, CDCl3)
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COSY NMR spectrum of oxeatamide E (27) (600 MHz, CDCl3)
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HSQC NMR spectrum of oxeatamide E (27) (600 MHz, CDCl3)
100
HMBC NMR spectrum of oxeatamide E (27) (600 MHz, CDCl3)
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Appendix D
Oxeatamide F
1H NMR spectrum of oxeatamide F (28) (600 MHz, CDCl3)
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13C NMR spectrum of oxeatamide F (28) (150 MHz, CDCl3)
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COSY NMR spectrum of oxeatamide F (28) (600 MHz, CDCl3)
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HSQC NMR spectrum of oxeatamide F (28) (600 MHz, CDCl3)
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HMBC NMR spectrum of oxeatamide F (28) (600 MHz, CDCl3)
106
Appendix E
Oxeatamide G
1H NMR spectrum of oxeatamide G (29) (600 MHz, CDCl3)
107
13C NMR spectrum of oxeatamide G (29) (150 MHz, CDCl3)
108
COSY NMR spectrum of oxeatamide G (29) (600 MHz, CDCl3)
109
HSQC NMR spectrum of oxeatamide G (29) (600 MHz, CDCl3)
110
HMBC NMR spectrum of oxeatamide G (29) (600 MHz, CDCl3)
111
Appendix F
Oxeatamide C
1H NMR spectrum of oxeatamide C (25) (600 MHz, d6-DMSO)
112
13C NMR spectrum of oxeatamide C (25) (150 MHz, d6-DMSO)
113
COSY NMR spectrum of oxeatamide C (25) (600 MHz, d6-DMSO)
114
HSQC NMR spectrum of oxeatamide C (25) (600 MHz, d6-DMSO)
115
HMBC NMR spectrum of oxeatamide C (25) (600 MHz, d6-DMSO)
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Abstract
During the course of this research five New Zealand marine sponges were investi-
gated. Detailed examination of one of the species, Darwinella oxeata, has resulted
in the isolation of ten compounds whose structures were elucidated using a variety of
spectroscopic techniques and a simple derivatisation reaction. These compounds were
identified as rearranged spongian diterpenes with the aplysulphurane backbone. Five
of these compounds have been previously reported, though two of them were originally
isolated from another marine sponge, Dendrilla membranosa. The five new compounds,
oxeatamides C to G (25–29), were found to have the same diterpene portion as the
oxeatamides already isolated from this sponge. They do, however, differ in the γ-lactam
side chain, which is proposed to be of amino acid origin. The new oxeatamides showed
moderate levels of cytotoxicity against the HL-60 cell line in MTT assays.
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